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ATRX INACTIVATION AND IDH1R132H DRIVE PREFERENTIAL SENSITIVITY TO
PROTON VS. X-RAY RADIOTHERAPY IN GLIOMA STEM CELLS
Ángel Adrián Garcés, B.S.
Advisory Professor: David Grosshans, M.D., Ph.D
Background: Glioma Stem Cells (GSCs) are self-renewable, treatment resistant cells in
the glioma tumor mass known to promote tumor development. In contrast to traditional
photon-based radiation therapy (XRT), proton radiation therapy (PRT) may induce more
complex DNA damage and therefore might have the potential to eliminate GSCs.
Although previous studies have individually linked IDH mutations, specifically
IDH1R132H, and ATRX inactivating mutations to improved patient outcomes and
suppressed DNA damage repair compared to their respective wild-types, the mechanisms
by which these two genetic alterations interact in GSCs treated with PRT compared to
XRT are currently unknown. We hypothesize that ATRXLoss and IDH1R132H both drive
preferential sensitivity to PRT compared to XRT.
Methods: Isogenic human GSC lines TS543-ATRXWT, TS543-ATRXLoss, MGG18IDH1WT, and MGG18-IDH1R132H were subjected to either XRT or PRT. Human GSC
lines TS603-ATRXWT/IDH1R132H and GS522-ATRXLoss/IDH1R132H were subjected to a
combination of Ivosidenib, a reversible selective IDH1R132 inhibitor, and either XRT or
PRT. Extreme limiting dilution analysis (ELDA) was used to calculate the active cell
frequency, a measure of GSC self-renewal. Post-radiation GSC viability was quantified
using the CellTiterGlo 3D assay at 14 days after XRT or PRT.1,2 The primary
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mechanisms of radiation-induced cell death were determined using the RealTime-Glo
Annexin V apoptosis and necrosis assay at 0-72 hours after irradiation.
Results: Using isogenic TS543 GSCs, ATRXLoss diminished cell viability and selfrenewal primarily by inducing cell death via apoptosis and secondary necrosis compared
to ATRXWT. Isogenic MGG18-IDH1R132H GSCs treated with PRT consistently exhibited
increased apoptotic and necrotic cell death compared to XRT. MGG18-IDH1WT
demonstrated increased apoptotic cell death after PRT compared to XRT. Finally,
combining Ivosidenib with either XRT or PRT diminished survival by upregulating
apoptotic and necrotic cell death in TS603-ATRXWT/IDH1R132H GSCs. However, the
opposite effects were observed in GS522-ATRXLoss/IDH1R132H GSCs.
Conclusions: PRT was more effective than XRT in inducing GSC death across several
cell lines. ATRX inactivation increased the efficacy of PRT via apoptotic and necrotic
cell death. IDH1R132H does not significantly improve radiation induced cell death in
ATRXWT GSCs. Combining IDH1R132H inhibitors with PRT in ATRXWT/IDH1R132H
GSCs may represent a novel treatment strategy to overcome radioresistance.
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Introduction
Clinical Standard of Care
Glioblastoma Multiforme
Glioblastoma Multiforme (GBM-Grade IV Glioma) is the most prevalent and
aggressive glioma in the USA to date, with a median survival of only 15 months.3-5
Although the exact symptoms experienced by a patient with GBM depends greatly on
tumor’s size and location, many patients exhibit seizures as well as headaches and
neurological deficits caused by a heightened intracranial pressure.6 Found predominately
in non-Hispanic white males, there are few established risk factors that are linked to
GBM development apart from ionizing radiation exposure. The high median age of
diagnosis (65 years old) and difficulty in performing complete tumor resection are
negative prognostic markers contributing to the uncurable nature of GBM.7
The diagnostic criteria set forth by the World Health Organization (WHO) in
2016 classifies gliomas from least to most malignant (grade I-IV) using histopathology
and molecular biomarkers.8 Although 90% of GBM tumors develop spontaneously with
no precursor lesions as primary GBM in elderly adult patients, young adult patients more
often exhibit malignant transformation of a low grade glioma (LGG-WHO Grade II) to a
high-grade glioma (HGG-Grade III) or secondary GBM. Patients harboring secondary
GBM tumors exhibit substantially increased median survival (5-10 years) compared to
patients with primary GBM (1-2 years).9,10 The current standard of care for glioblastoma
involves surgical removal followed by chemotherapy, especially with the DNA alkylating
agent temozolomide (TMZ), and radiation therapy.3,11,12
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Low-Grade Gliomas
Although treatments for LGGs are not as standardized as GBM, maximal safe
surgical resection, chemotherapy, and radiation therapy are still frequently utilized in the
clinic.13 Diffuse grade II and III gliomas can be subclassified into oligodendrogliomas
(ATRX wild-type, IDH mutant, chromosomal 1p/19q co-deletion) and astrocytomas
(ATRX inactivation, IDH mutant, chromosomal 1p/19q intact) by using a combination of
molecular and histopathologic analytical approaches (Figure 1).11 Patients with LGGs
commonly experience uncontrolled seizures and can be further identified as “low-risk
(age<40 years old AND gross total resection)” or “high-risk (age>40 years old OR
subtotal resection)” depending on age and surgical approach. The specific surgical
technique used to extract the tumor is decided upon based on how close the tumor is to
areas in the brain that control important motor or sensory functions.14
The importance of resecting as much tumor mass possible cannot be understated
as Smith et. al (2008) demonstrated that the five-year patient survival rate drops
substantially from 97% to 76% if <90% of the tumor mass is removed.15 While the
probability of tumor recurrence is significantly elevated for high-risk patients, especially
those with wtIDH tumors, the decision on whether or not to pursue post-operative
chemoradiotherapy remains unclear. This decision is especially difficult in low-risk
patients with a potential 5-year recurrence rate of 52% who might receive more benefit
from routine MRI surveillance.16 Therefore, it is important to develop new therapeutic
modalities based on a tumor’s molecular profile to diminish the risk of both tumor
recurrence and malignant transformation, which is seen in upwards of 72% of all LGG
cases within 3-5 years of diagnosis (Figure 2).17
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Figure 1: Histopathological and genetic profiles of low-grade gliomas.
Representative hematoxylin and eosin (H&E) photomicrographs of (A) astrocytomas
and (B) oligodendrogliomas. Astrocytomas are characterized by extended cell shape as
well as inconsistently shaped, hyperchromatic nuclei. Oligodendrogliomas exhibit round
shaped nuclei with perinuclear haloes. IDH: Isocitrate Dehydrogenase. ATRX: alphathalassemia X-linked mutant retardation syndrome. 1p/19q co-deletion: whole arm loss
of chromosomes 1p/19q.
Source: Oberheim Bush NA, Chang S: Treatment Strategies for Low-Grade Glioma in
Adults. Journal of Oncology Practice 12:1235-1241, 2016. Used with permission.
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Figure 2: Low-grade glioma to glioblastoma multiforme malignant transformation.
LGG malignant transformation is defined starting from grade II glioma. Grade I gliomas
(most common: pilocytic astrocytoma) are not included since they are generally
considered benign and are frequently cured with surgery alone. Grade I gliomas are
primarily found only in pediatric patients, while grade II-IV gliomas are found primarily
in adult patients.18
Figure created using Biorender.com.
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Molecular Diagnostic Tools
Isocitrate Dehydrogenase Mutations
Isocitrate Dehydrogenase (IDH) mutations represent a viable therapeutic target
for impairing malignant transformation due to their high prevalence in LGGs and
secondary GBMs. However, these mutations are rarely found in primary GBMs.19 The
most common IDH mutations present in LGGs associated with tumorigenesis are
heterozygous missense mutations at arginine 132 of the IDH1 isoform (IDH1R132), at
arginine 140 of the IDH2 isoform (IDH2R140), or at arginine 172 of the IDH2 isoform
(IDH2R172). IDH1 functions in the cytosol while IDH2 functions in the mitochondria.20
However, the mutation of IDH1 arginine 132 to histidine (IDH1R132H) is by far the most
prevalent in clinical care representing 70-80% of low-grade glioma (LGG) and secondary
GBM tumor cases.21,22
IDH1R132H is often the first genetic alteration to occur in patients, presenting in
approximately 80% of grade II-III gliomas.23,24 An analysis of 486 patients conducted by
Tom et. al (2019) discovered that patients harboring IDH1R132H/chromosomal
1p19qcodeletion (oligodendrogliomas) exhibit higher overall survival and longer time to
malignant transformation compared to patients with IDH1R132H/chromosomal 1p19qintact
and IDHWT tumors.25 The repeated association of IDH mutations with favorable clinical
prognoses has motivated many studies into investigating the biomolecular changes
exhibited by cells harboring IDH mutations. A leading hypothesis by which IDH1R132H
specifically drives improved patient survival and therapeutic response is due to the
neomorphic production of 2-Hydroxyglutarate (2-HG) from alpha-ketoglutarate (α-KG)
in the cytosol compared to IDH1WT (Figure 3). The accumulation of supraphysiological
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2-HG concentrations inside cells with IDH1R132H serves as a critical biomarker and
competitive inhibitor of α-ketoglutarate dependent dioxygenases, which are known to
regulate the tumor epigenome, cell differentiation, angiogenesis, and hypoxic stress.26-28
The inhibition of α-ketoglutarate dependent dioxygenases due to heightened
concentrations of 2-HG results in a variety of intracellular changes that are correlated
with improved patient survival (Figure 4).29
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Figure 3: IDH1R132H induces production of (R)-2-Hydroxyglutarate
(A) IDH1WT converts isocitrate and NADP+ into α-ketoglutarate, NADPH, and CO2.
(B) IDH1R132H reduces the α-ketoglutarate created by IDH1WT into the oncometabolite
(R)-2-Hydroxyglutarate (2-HG).
This figure was created by combining the ideas presented in Figure 2 of “Molenaar RJ,
Maciejewski JP, Wilmink JW, et al: Wild-type and mutated IDH1/2 enzymes and therapy
responses. Oncogene 37:1949-1960, 2018” and Figure 3 of “Tommasini-Ghelfi S,
Murnan K, Kouri FM, et al: Cancer-associated mutation and beyond: The emerging
biology of isocitrate dehydrogenases in human disease. Sci Adv 5:eaaw4543, 2019.”
Both articles are licensed under the Creative Commons Attribution Non-CommercialShareAlike 4.0 International License.
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Figure 4: The effects of (R)-2-Hydroxyglutarate in IDH mutant gliomas.
The oncometabolite (R)-2-Hydroxyglutarate (2-HG) acts as a competitive inhibitor of αketoglutarate dependent dioxygenases, which promotes changes in reactive oxygen
species production, dsDNA damage response, epigenetic states, and angiogenesis.
Source: Gagné et al-Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to
Cellular Signaling. Trends in cell biology 27:738-752, 2017. Used with permission.
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Since 2-HG is known to enter the nucleus from the cytosol, changes in the
epigenetic landscape of IDH1R132H tumors compared to IDH1WT tumors are currently a
highly active area of research. An analysis of GBM samples from The Cancer Genome
Atlas (TCGA) conducted by Noushmehr et al (2010) first identified a connection between
IDH1R132H and the glioma-CpG island methylator phenotype (G-CIMP). This phenotype
(G-CIMP+) was found predominately in proneural GBMs and was associated with a
longer survival time after diagnosis compared to G-CIMP negative (G-CIMP-) tumors.
The absence of the G-CIMP phenotype was found mainly in mesenchymal GBM cells.30
A follow-up study conducted by de Souza et al (2018) further classified IDH mutant, GCIMP+ tumors into G-CIMP high and G-CIMP low. G-CIMP high tumors exhibited
significantly higher levels of DNA methylation and improved survival outcomes
compared to patients with G-CIMP low tumors, despite the fact that both subtypes
harbored IDH mutations.31 These findings establish the potential value of DNA
hypermethylation due to histone demethylase inhibition by 2-HG as a future prognostic
marker for patients with LGG or secondary GBM.
Although the mechanisms by which cytosolic 2-HG produced by IDH1R132H
promotes favorable patient outcomes are still under investigation, several reports have
presented evidence to suggest that IDH1R132H promotes favorable outcomes to radiation
therapy. Sulkowski et al (2017) demonstrated that 2-HG directly contributes to the
creation of dsDNA lesions by ionizing radiation and is implicated in impairing dsDNA
damage repair via Homologous Recombination (HR) in HCT116 and HeLa cells. Further
studies demonstrated that in vitro radiosensitivity in IDH1R132H human astrocytes, glioma
stem cells, and cholangiocarcinoma is further enhanced in the presence of poly(ADP-
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ribose) polymerase (PARP) inhibitors, such as Olaparib and Veliparib.32,33 In addition to
the increased dsDNA damage and impaired dsDNA lesion repair exhibited in irradiated
IDH1R132H cells, Yin et al (2019) demonstrated that IDH1R132H suppresses the expression
of TIGAR (TP53-induced glycolysis and apoptosis regulator) due to the presence of the
heterochromatin associated epigenetic alteration H3K9me3 at TIGAR promoters.34
TIGAR is a critical gene that impairs the production of fructose-2,6-bisphosphate, which
suppresses glycolysis as well as reactive oxygen species (ROS) production.35 Yu et al
(2020) built upon these results by demonstrating that isogenic IDH1R132H U87
glioblastoma cells naturally exhibit increased ROS production without the addition of
external agents compared to IDH1WT U87 glioblastoma cells.36 In the subpopulation of
highly chemoradioresistant human glioma stem cells, IDH1R132H is known to decrease
migration and invasion while simultaneously increasing apoptosis and differentiation.37
These findings implicate IDH1R132H as a highly indispensable factor in ensuring that
radiation therapy can effectively induce dsDNA damage and cancer cell death.
In addition to radiosensitivity, several studies have linked IDH mutations to
improved chemotherapeutic sensitivity. Specifically, IDH1R132H has been implicated in
promoting glioma cell death after treatment with the DNA alkylating agent temozolomide
(TMZ), which is considered part of the standard of care for glioblastoma, through a
variety of mechanisms. One highly studied mechanism of IDH1R132H driven TMZ
sensitivity is the suppression of NADPH and GSH production, possibly due to the
decreased expression of the antioxidant Nrf2 in U87 and U251 IDH1R132H glioblastoma
cells.38,39 TMZ sensitivity is further enhanced when administered in combination with
PARP inhibitors, as demonstrated by increased γH2AX foci Lu et al (2017) in U87

10

IDH1R132H glioblastoma cells.40 Sule et al (2021) further built upon these findings by
establishing that U87- IDH1R132H and T229-IDH1R132H glioblastoma cells as well as
HCT116-IDH1R132H colon cancer cells treated with a combination of PARP inhibitors
and ATR inhibitors experienced decreased clonogenic survival, suppressed HR,
premature mitotic entry, and increased apoptosis.41 Although several studies have
established an association between IDH1R132H and improved chemotherapeutic
sensitivity, the use of IDH1R132H itself as a therapeutic modality has not been explored
until recently. Promising preclinical data has demonstrated the efficacy of IDH1R132H
peptide vaccines through their ability to bind onto neoepitopes on MHC class II and
induce CD4+ Th cell IFN-γ production.42 This data led to the development of a Phase I
clinical trial (Platten et al 2021, ClinicalTrials.gov identifier NCT02454634) that
demonstrated vaccine induced T and B cell immunogenicity in 33 patients with either
grade III or IV IDH1R132H astrocytomas.43 Although several studies have investigated the
biomolecular mechanisms by which IDH mutations independently confer positive patient
prognosis, the interactions between IDH mutations and other LGG genetic alterations are
still under active investigation.
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Alpha-Thalassemia X-linked Mutant Retardation Syndrome Mutations
Inactivating mutations of the N-terminal chromatin binding ATRX-DNMT3DNMT3L (ADD) domain in the ATRX protein (alpha-thalassemia X-linked mutant
retardation syndrome; ATRXLoss) represents another important genetic alteration and
potential therapeutic target specific to patients with astrocytomas.44 Since ATRXLoss
commonly presents alongside IDH mutations in tumors with intact 1p/19q chromosomes,
the World Health Organization modified the diagnosis of astrocytomas to include these
genetic alterations alongside established histopathological guidelines.11,45 ATRXLoss is
predominately found in young adult patients with grade II astrocytomas (median age=30
years old) and grade III anaplastic astrocytomas (median age=35 years old). ATRXLoss
has frequently been associated with improved progression-free and overall survival
compared to tumors with wild-type ATRX expression (ATRXWT).44-46 This also holds
true for adult patients with ATRXLoss GBM and pediatric patients with ATRXLoss highgrade gliomas (HGGs).47,48
ATRX itself is a ATP dependent SWI/SNF2 chromatin remodeling protein that
maintains genome stability by depositing histone H3.3 at telomeres and pericentromeric
heterochromatin when combined with its transcriptional co-factor DAXX (Death-Domain
Associated Protein; See Figure 5).46 In gliomas, ATRXLoss has been linked to promoting
the development of the alternative lengthening of telomeres (ALT) phenotype. This is a
homologous recombination (HR) based mechanism for telomere maintenance that does
not require telomerase. The main function of ALT is to help cancer cells proliferate
indefinitely to evade apoptosis or senescence.49 ALT+ gliomas are characterized by the
presence of tumor suppressing promyelocytic leukemia nuclear bodies (PML-NBs),
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ultrabright telomeric DNA foci, heterogeneous telomere length due to inter/intrachromosomal

telomere

exchange,

and

extrachromosomal

DNA

C-circles.46,50

Mechanistically, Li et al (2019) established that the ATRX-DAXX-H3.3 complex is
required to protect chromosomal telomere structure and to maintain normal telomere
DNA replication. Loss of ATRX or DAXX induces delayed telomere replication stress
and dysfunction that cannot be fixed by telomerase, thereby resulting in a dependence on
the ALT mechanism to maintain telomere length and promote cell immortalization
(Figure 6).51
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Figure 5: Intracellular characteristics of ATRXWT and ATRXLoss cells
ATRX has the capability to function both dependently and independently of its
transcriptional co-factor DAXX to promote chromatin stability and telomere repair.
Source: Haase S, Garcia-Fabiani MB, et al: Mutant ATRX: uncovering a new therapeutic
target for glioma. Expert opinion on therapeutic targets 22:599-613, 2018. “Taylor &
Francis is pleased to offer reuses of its content for a thesis or dissertation free of charge
contingent on resubmission of permission request if work is published.”
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Figure 6: ATRXLoss promotes telomere maintenance via ALT.
Although ATRX intact cells can repair telomere length through the conventional
telomerase pathway, ATRXLoss cells lose the ability to recruit H3.3 and localize to
telomere ends, thereby requiring the use of the alternative lengthening of telomeres
(ALT) pathway.
Source: Haase S, Garcia-Fabiani MB, et al: Mutant ATRX: uncovering a new therapeutic
target for glioma. Expert opinion on therapeutic targets 22:599-613, 2018. “Taylor &
Francis is pleased to offer reuses of its content for a thesis or dissertation free of charge
contingent on resubmission of permission request if work is published.”
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Alongside its role in promoting the development of the ALT phenotype, several
reports have established a connection between ATRXLoss and radiation induced
cytotoxicity via the creation of dsDNA breaks. Koschmann et al (2016) discovered that
mouse GBM cells harboring shp53/NRAS/shATRX exhibited significantly diminished
cell proliferation rates in vitro compared to mouse GBM cells with shp53/NRAS/intact
ATRXWT due to heightened dsDNA damage from exposure to increasing doses of
ionizing radiation. The authors present strong evidence to suggest that ATRXLoss
significantly impairs the successful resolution of dsDNA lesions via NHEJ. No
significant changes in HR mediated DNA damage repair were attributed to ATRXLoss.48
On the contrary, Juhász and colleagues (2018) established that ATRX is indispensable to
radiation-induced dsDNA lesion repair due to its function downstream of RAD54 by
complexing with PCNA and RFC-1 to form double Holliday junctions and promote sister
chromatid exchange.52 Follow up studies confirmed that the repair of two-ended dsDNA
breaks via HR-DSBR (Double-Strand Break Repair) is predominately driven by ATRX
while repair via HR-SDSA (Synthesis-Dependent Single Strand Annealing) is
predominately driven by RECQ5. Despite the risks of carcinogenesis posed by loss of
heterozygosity associated with the formation of crossover products, ATRX-driven HR
repair is the dominant pathway to repair two-ended dsDNA breaks created by ionizing
radiation in HeLa, U2Os, and 82-6 cell lines. Inhibiting access to either one or both of
these modes of HR repair via siRNA knockdown (siATRX or siRECQ5) results in
enhanced dsDNA breaks as quantified by γH2AX foci.53
Another mechanism by which ATRXLoss drives radiosensitivity is through the
formation of DNA G-quadruplexes (G4) secondary structures and chromosome breaks, as
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demonstrated by Wang et al (2019) in isogenic normal human astrocyte (NHA) and
human glioma stem cells (GSC). ATRXWT is known to protect cells from genomic
instability by binding and resolving G4 quadruplexes through the deposition of H3.3 at
G-rich sites as well as protecting stalled replication forks from collapsing and causing
DNA damage.46,54,55 Wang et al (2019) report that although ATRXLoss alone was
insufficient to induce apoptotic cell death, isogenic NHAs and GSCs harboring ATRXLoss
exhibited dramatically lower cell viability, significant apoptotic cell death, higher
phosphorylated CHK1 expression, and higher counts of γH2AX/53BP1 dsDNA damage
foci when treated with G4 stabilization compounds (CX-3543, Pyridostatin, or CX-5461)
compared to ATRXWT cells. This effect was further pronounced when combining G4
stabilization agents with ionizing radiation, which demonstrates the important role of
ATRXWT in protecting cells from radiation induced dsDNA damage.55,56 These findings
suggest that combining G4 stabilization agents with ionizing radiation might prove to be
an effective new treatment option for patients with astrocytomas.
Due to the prevalent use of isogenic cell lines to study the functions of ATRXLoss
and IDH mutations independently in vitro, the combined effects of IDH mutations and
ATRXLoss in the same cell are still not completely understood. ATRXLoss and IDH1R132H
are known to work together in driving the development of the ALT+ phenotype and
gliomagenesis in vitro.57 Additionally, ATRXLoss has previously been implicated in
promoting transwell migration in IDH1R132H GSCs compared to ATRXWT, possibly due
to the heightened expression of the GNA13 protein.58 These findings implicate a specific
biomolecular mechanism that can be targeted to ensure effective gross total surgical
resection of astrocytomas. Although ATRXLoss also drives the formation of DNA G4

17

quadruplexes in isogenic GSCs, IDH1R132H does not significantly enhance G4
development when expressed alongside ATRXLoss in the same cell.55 Human astrocytes
and glioblastoma cells treated with increasing concentrations of known PARP inhibitor
Olaparib exhibited a similar trend with regards to clonogenic survival and phosphorylated
CHK1 (Ser-345) expression, a measure of DNA replication stress due to its affinity for
ssDNA breaks with ATR and RPA proteins, when comparing cells with ATRXLoss or
IDH1R132H alone compared to ATRXLoss and IDH1R132H. PARP inhibitors appear to
synergize well with ATR inhibitors to impair cell cycle arrest in S phase and allow the
repair of ssDNA breaks in isogenic ATRXLoss and IDH1R132H glioblastoma cells.41,59
Although this synergistic effect has not yet been explored in glioma cells harboring both
ATRXLoss and IDH1R132H, these results demonstrate promising evidence to suggest that
G4 stabilization compounds might synergize well with ATR and PARP inhibitors to
further promote the efficacy of radiation induced DNA damage and cytotoxicity in lowgrade glioma cells.
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Glioma Stem Cells
Although IDH mutations and ATRXLoss serve as valuable molecular markers in
glioma diagnosis, the development of new therapeutic modalities that enhance patient
survival is further complicated due to the intratumoral genetic, epigenetic, and
phenotypic heterogeneity present in LGG and GBM.60,61 One of the key drivers of tumor
heterogeneity are the glioma stem cells (GSC) in the tumor mass, which are heavily
implicated in post-treatment tumor recurrence and diminished patient survival.
The cancer stem cell (CSC) hypothesis states that tumors develop from selfrenewable, undifferentiated cells, similar to how normal stem cells differentiate into a
diverse array of cell types in the human body with a set lifetime.62 Lapidot et al (1994)
were the first to identify CSCs using acute myeloid leukemia as their model system.63
Since then, CSCs have been found in various types of solid tumors, including
glioblastoma, breast, and pancreatic cancers.64 The discovery of glioma and glioblastoma
tumor initiating stem cells in particular by Singh et al in 2003 has spurred the
development of many studies working to understand the mechanisms by which GSCs are
involved in tumor formation and how they impact therapeutic sensitivity.64 Although
convincing evidence for the existence of GSCs has been presented by several research
groups, the identification of one specific biomarker to easily find GSCs in the tumor mass
is still an active area of investigation. Several cell surface markers are known to be
upregulated in GSCs, such as CD133, CD15, LICAM, and SOX2.65,66 However, these
cell surface markers are not ubiquitous enough in all GSCs to be designated as
biomarkers. Proneural GSCs exhibit heightened CD133 expression and grow as
neurospheres in culture while mesenchymal GSCs express lower levels of CD133 on
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their cell surfaces and grow semi-adherantly in culture.67,68 The identification of GSCs
becomes further complicated due to their ability to dynamically change their cell surface
receptors in response to the upregulation of neurodevelopmental transcription factors,
such as POU3F2, SOX2, SALL2, and OLIG2 as identified by Suva et al (2014).69,70 The
function of a GSC also depends greatly on its specific microenvironmental “niche,” the
most common of which are the perivascular tumor niche, the hypoxic niche, and the
invasive niche in GBM.71,72 The heavily dynamic nature of GSCs has led to some to
question the CSC hypothesis altogether and suggest that instead of operating as a distinct
cell subpopulation, these cells are merely adapting to microenvironmental cues to evade
cytotoxicity and promote tumor survival.73 Despite the genetic and phenotypic plasticity
exhibited by GSCs, many new treatments are focused on modulating the “stemness” of
GSCs to ensure their elimination and inability to promote secondary tumor formation.72
GSCs are able to differentiate into several different cell types within the tumor
microenvironment, such as stromal cells, vasculature, fibroblasts, and tumor associated
macrophages.65,72 GSCs also contribute to tumor chemoradioresistance due to their ability
to indefinitely self-renew as well as transition back to an undifferentiated state after
differentiating into a tumor cell as a means to avoid elimination by cytotoxic therapies.
Dahan et al (2014) proved that glioblastoma cells exhibit plasticity and can dedifferentiate into a cancer stem-cell like state when exposed to ionizing radiation, even at
subtoxic doses, via the upregulation of the anti-apoptotic protein survivin.74 Additionally,
Bao et al (2006) demonstrated that human glioma xenograft treated with ionizing
radiation caused a shift towards an increase of CD133+ GSCs both in vitro and in vivo.
CD133+ GSCs exhibited higher post-radiation clonogenic surviving fraction, a decrease
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in cleaved caspase-3, and increased expression of key DNA damage repair checkpoint
proteins, including pATM, pRAD17, pChk1, and pChk2, thereby promoting the
development of a radioresistant phenotype.75 Balbous et al (2016) built upon these
findings and demonstrated the efficacy of reversing the radioresistant phenotype of GSCs
through the combination of RAD51 inhibitors with ionizing radiation.76 The
radioresistance of GSCs can also be understood through the suppression of reactive
oxygen species (ROS) scavenger production generally exhibited by CSCs, thereby
leading to decreased intracellular oxidative stress.77-79
With regards to chemotherapeutic resistance, Temozolomide treated GSCs
created from the de-differentiation of GBM cells (induced GSCs, or iGSCs) exhibited
higher proliferation rates and survival rates than the original GBM cells due to the
activation of the NOTCH1 and Wnt/β-Catenin pathways as well as the expression of
hypoxia-inducible factors (HIF) 1α and 2α.80,81 The unique ability of GSCs to indefinitely
self-renew, differentiate, and de-differentiate results in the generation of clones with
various levels of chemoradioresistance scattered throughout the tumor.82,83 These
characteristics ultimately work to promote gliomagenesis and tumor diffusion throughout
the brain, thereby increasing the difficulty of surgically resecting the entirety of the tumor
mass from the patient (Figure 7). Therefore, the elimination of the entire GSC population
to prevent unfavorable patient prognoses cannot be understated. For these reasons, I
selected isogenic glioma stem cells as the model system for my in vitro studies to identify
the mechanisms by which ATRXLoss and IDH mutations drive radiation sensitivity.
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Figure 7: A mechanistic summary of cancer stem cell driven tumor recurrence.
Cancer Stem Cells (CSC) possess the innate ability to self-renew and differentiate into
any type of cell within the tumor. The chemoradioresistant and immunosuppressive
nature of CSCs make their elimination from the tumor quite difficult, which may result in
secondary tumor formation. Figure created using Biorender.com.
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Radiation Therapy: Protons vs. X-Rays
A highly promising therapeutic modality for targeting and effectively treating the
entirety of the glioma mass and GSC subpopulation is proton radiation therapy (PRT).
First introduced in the 1950s, PRT may preferentially target tumor cells while sparing
healthy tissues compared to conventional X-ray therapy (XRT).84-86 X-rays deposit a
significant entry dose before reaching the tumor and a significant exit dose after leaving
the tumor. However, protons deposit a comparatively lower entry dose before coming to
a halt at the Bragg peak, defined as the depth at which a proton of a given energy
maximizes its dose deposition.86,87 Protons have the added benefit of not depositing an
exit dose, thereby reducing the risk of off-target radiation toxicity.
In addition to its favorable dose-depth profile, PRT is known to induce more
clustered and complex lethal dsDNA breaks (DSBs) compared to conventional XRT.
This is indicated by the enlarged size and prevalence of gH2AX foci in vitro.88 The
resolution of these clustered DSBs relies heavily on proteins involved in the homologous
recombination (HR) DNA damage repair pathway, especially RAD54, compared to nonhomologous end joining (NHEJ).89 However, despite these biological advantages, each
mono-energetic proton beam creates a “pristine” Bragg peak that is too thin to deliver the
maximum dose to the entirety of the tumor. To solve this problem, a “Spread-Out” Bragg
peak is created by delivering several proton beams of various energies together to create
an area with uniform dose distribution. This ensures that the entirety of the tumor
receives an equal dose while also minimizing off-target radiation toxicity to sensitive
areas around the tumor (Figure 8).90
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The density of ionization events responsible for DSBs is directly proportional to
Linear Energy Transfer (LET), which refers to the energy lost along the path length of a
proton beam. The LET of a proton beam directly impacts its Relative Biological
Effectiveness (RBE), defined as a ratio of XRT to PRT dose that achieves a given
biological effect.91 Specifically, Carter et al (2018) demonstrated that high LET protons
induce higher levels of single stranded and double stranded DNA damage as well as
ubiquitination on H2B lysine 120 compared to low LET protons in HeLa and
oropharyngeal squamous cell carcinoma lines.92 Motivated by previous results
demonstrating the efficacy of high LET protons in inducing cancer cell death, Ma et al
(2020) created a modified proton SOBP with a higher weight placed on low-energy, high
LET proton beams without impacting the dose delivered. This new “downslope” dosedepth profile successfully delivered a higher LET, which resulted in an increased number
of persistent γH2AX and 53BP1 dsDNA damage foci as well as decreased clonogenic
survival in H460 lung cancer cells.93 These results demonstrate the importance of
optimizing future treatment plans to emphasize the delivery of high LET protons for
maximum therapeutic efficacy.
Although PRT offers benefits over conventional XRT, the diffuse nature of LGGs
presents difficulties in eliminating the entirety of the tumor mass and GSC population.94
Alan Mitteer et al (2015) demonstrated that PRT induced DSBs and GSC toxicity is
dependent upon the successful generation of ROS.95 However, the understanding of how
key genetic alterations used in the diagnosis of low-grade gliomas, specifically IDH
mutations and ATRX inactivation, impact the cell death mechanisms that govern the
efficacy of XRT vs. PRT induced GSC toxicity remain unknown.
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Figure 8: Traditional spread-out Bragg peak (SOBP) for proton radiotherapy.
(A) The percent dose-depth curve for a proton SOBP delivered using 16 discrete energies
at The University of Texas MD Anderson Cancer Center. Higher energy beams are
traditionally weighted more heavily than lower energy beams when creating a traditional
SOBP. (B) The normalized dose-depth curve demonstrates the rising LET towards the
SOBP distal fall off point.
Source: Ma D, Bronk L, Kerr M, et al: Exploring the advantages of intensity-modulated
proton therapy: experimental validation of biological effects using two different beam
intensity-modulation patterns. Scientific Reports 10, 2020. “This is an open access article
distributed under the terms of the Creative Commons CC BY license, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.”
25

Hypothesis and Specific Aims
Specific Aim 1: To determine the independent effects of ATRXLoss and IDH1R132H on
the viability and self-renewal of irradiated human glioma stem cells.
Aim 1A: To investigate the efficacy of ATRXWT and ATRXLoss to impair cell
viability and self-renewal after treatment with XRT vs. PRT in human glioma stem cells.
Aim 1B: To investigate the efficacy of IDH1WT and IDH1R132H to impair cell
viability and self-renewal after treatment with XRT vs. PRT in human glioma stem cells.

Specific Aim 2: To identify the primary post-XRT and post-PRT cell death
mechanisms in ATRXLoss isogenic human glioma stem cells.
Aim 2A: To quantify the extent of apoptotic and necroptotic cell death in
ATRXWT and ATRXLoss human glioma stem cells treated with XRT.
Aim 2B: To quantify the extent of apoptotic and necroptotic cell death in
ATRXWT and ATRXLoss human glioma stem cells treated with PRT.

Specific Aim 3: To elucidate the efficacy of combining IDH1R132H inhibitors with
radiation therapy in ATRXWT and ATRXLoss human glioma stem cells.
Aim 3A: To investigate the effects of combining radiation therapy (XRT or PRT)
with Ivosidenib, a selective IDH1R132H inhibitor, on cell viability, apoptosis, and necrosis
in ATRXWT/IDH1R132H human GSCs.
Aim 3B: To investigate the effects of combining radiation therapy (XRT or PRT)
with Ivosidenib, a selective IDH1R132H inhibitor, on cell viability, apoptosis, and necrosis
in ATRXLoss/IDH1R132H human GSCs.
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Central Hypothesis
I hypothesized that ATRX inactivation and IDH mutations (specifically
IDH1R132H) work together to stimulate apoptotic and necrotic cell death in GSCs more
effectively after PRT compared to XRT.
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Materials and Methods
Glioma Stem Cell Culture
TS543 (Glioblastoma) and TS603 (WHO grade III anaplastic oligodendroglioma)
GSCs were isolated by Drs. Cameron W. Brennan and Ingo Mellinghoff at Memorial
Sloan Kettering Cancer Center. These cells were gifted to A Garcés by Dr. Jason Huse at
MD Anderson Cancer Center in Houston, TX. TS543-ATRXWT, TS543-ATRXLoss, and
TS603 GSCs were cultured in suspension as neurospheres in DMEM/F12 media (Gibco
10-090-CV) with 2% B27 supplement without Retinoic Acid (Life Technologies Corp.,
12587-010), 1% penicillin-streptomycin-amphotericin B antibiotic (Cellgro #30-004-Cl),
50 µg/mL plasmocin anti-mycoplasma prophylactic (InvivoGen ant-mpp), 2 µg/mL
Heparin (StemCell Technologies 07980), 20 ng/mL human recombinant Epidermal
Growth Factor (EGF; StemCell Technologies 78006.1), and 20 ng/mL human
recombinant basic Fibroblast Growth Factor (bFGF; Stemcell Technologies 78003).
TS543-ATRXLoss was created using an shRNA construct against ATRX (sh590) and
selected for using 1 µg/mL puromycin (StemCell Technologies 73342) at least 24 hours
prior to irradiation. TS543-ATRXLoss grew primarily in an adherent manner while TS543ATRXWT primarily grew as neurospheres in suspension. TS603 endogenously expresses
the heterozygous IDH1R132H mutation and ATRXWT.96,97 The cells were passaged and
received fresh media every 3-5 days. After thawing from -80°C, the cells were cultured a
maximum of four passages.
MGG18 cell culture was performed as described previously in Tateishi et al
(2015).98 MGG18 is an IDH1WT patient derived GSC line generously donated by Dr.
Daniel P. Cahill at Massachusetts General Hospital. MGG18-IDH1WT and MGG1828

IDH1R132H were cultured in suspension as neurospheres in neurobasal media with 2%
B27 supplement without Retinoic Acid (Life Technologies Corp., 12587-010), 0.5% N2
supplement (Gibco/Invitrogen #17502-048), 0.5% penicillin-streptomycin-amphotericin
B antibiotic (Cellgro #30-004-Cl), 3 mM L-Glutamine (Cellgro #25-005-Cl), 50 µg/mL
plasmocin anti-mycoplasma prophylactic (InvivoGen ant-mpp), 20 ng/mL human
recombinant EGF (R&D Systems #236-EG-200, Minneapolis, MN) , and 20 ng/mL
human recombinant bFGF (Peptrotech #100-18B, Rocky Hill, NJ). IDH1R132H was
activated using 1 µg/mL doxycycline (StemCell Technologies 72742) at least 24 hours
prior to irradiation. The cells were passaged and received fresh media every 3-5 days.
After thawing from -80°C, the cells were cultured a maximum of four passages.
GS 5-22 is an ATRXLoss/IDH1R132H GSC line derived from a patient with
secondary GBM and were graciously donated by Dr. Eric Sulman while at MD Anderson
Cancer Center in Houston, TX.99 GS 5-22 was cultured in suspension as neurospheres in
DMEM/F12 media (Gibco 10-090-CV) with 2% B27 supplement without Retinoic Acid
(Life Technologies Corp., 12587-010), 1% penicillin-streptomycin-amphotericin B
antibiotic (Cellgro #30-004-Cl), 50 µg/mL plasmocin anti-mycoplasma prophylactic
(InvivoGen ant-mpp), 2 µg/mL Heparin (StemCell Technologies 07980), 20 ng/mL
human recombinant Epidermal Growth Factor (EGF; StemCell Technologies 78006.1),
and 20 ng/mL human recombinant basic Fibroblast Growth Factor (bFGF; Stemcell
Technologies 78003). The cells were passaged and received fresh media every 3-5 days.
After thawing from -80°C, the cells were cultured a maximum of four passages.
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X-ray and Proton Irradiations
Based on the methods presented in Ma et al (2020),93 all X-ray irradiations were
conducted with a 6 MV linear accelerator (Truebeam, Varian Medical Systems, Palo
Alto, CA) available at the MD Anderson Proton Therapy Center (PTC) in Houston, TX.
GSCs were seeded in 96 well ultra-low attachment plates and irradiated at a solid water
equivalent depth of 10 cm using a 30 cm x 30 cm field size. Proton irradiations were
conducted using a 100 MeV proton passive scattered beam with a water equivalent range
of 4.3 cm and 1 cm spread-out Bragg peak (SOBP) width at the MD Anderson PTC.
GSCs were seeded in 96 well ultra-low attachment plates and irradiated at a solid water
equivalent depth of 3.8 cm, which is approximately at the center of the SOBP (Figure 9).
All X-ray and proton irradiations were conducted on the same day. All cells experienced
a 10-minute transportation time to the PTC and were incubated at 37°C and 5% CO2 at
the PTC while waiting for irradiation.

Figure 9: Custom proton SOBP created for all GSC irradiations.
The proton SOBP was constructed based on the ~300 nm spheroid diameter measured
prior to irradiation. The original SOBP was created by Mr. Conor McFadden. Dosimetry
was conducted by Mr. Conor McFadden and Dr. David Flint. Created in Biorender.
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Scanning Electron Microscopy
Scanning Electron Microscopy was performed by Mr. Kenneth Dunner at the MD
Anderson High Resolution Electron Microscopy Facility. The exact protocol reported
below can be found at this link and in Bu et al (2007).100
At 72 hours post-irradiation, TS543-ATRXWT and TS543-ATRXLoss were
suspended in 500-1000 µL of Accutase for 8 minutes, washed twice in PBS, and then
fixed in 4% paraformaldehyde. Fixed samples were first washed with 0.1 M cacodylate
buffer (pH 7.3) and post fixed using 1% cacodylate buffered osmium tetroxide.
Subsequently, the samples were washed with 0.1M cacodylate buffer and then distilled
water. The samples were then treated with Millipore-filtered 1% aqueous tannic acid,
washed in distilled water, treated with Millipore-filtered 1% aqueous uranyl acetate, and
then rinsed thoroughly with distilled water. Sample dehydration was conducted with
increasing concentrations of ethanol followed by transfer to increasing concentrations of
hexamethyldisilazane (HMDS). After air drying overnight, the samples were mounted
onto double-stick carbon tabs (Ted Pella. Inc., Redding, CA) and coated under vacuum
using a Balzer MED 010 evaporator (Technotrade International, Manchester, NH) with
platinum alloy for a thickness of 25 nm, then immediately flash carbon coated under
vacuum. The samples were transferred to a desiccator for examination in a JSM-5900
scanning electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating
voltage of 10 kV. Funding was made available for this facility through the NIH CCSG
grant P30CA016672.
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Apoptosis and Necrosis Assay
All GSCs were seeded at 2000 cells/well in 96 well ultra-low attachment plates
and allowed to grow for 1-2 days to form spheroids prior to irradiation. 100, 1000, or
10000 nM Ivosidenib (MedChemExpress HY-18767) was suspended in media containing
0.1% DMSO 1-2 hours prior to irradiation. The extent of both apoptosis and necrosis was
quantified using the RealTime-Glo™ Annexin V Apoptosis and Necrosis assay starting
at approximately 1 hour after irradiation. Luminescence (early apoptosis) and florescence
(secondary necrosis) measurements were taken using the PerkinElmer Victor X3
multimode plate reader (Part Number 2030-0050) every 8 hours for 48 hours and at 72
hours post-irradiation (Figure 10). To multiplex with the CellTiter-Glo® 3D cell
viability assay, the media was refreshed after 72 hours (Figure 11-12). All data was
normalized to the initial measurements collected at either t=0 hours or 0 Gy and
presented as a percent fold change. Results represent an average of at least two biological
replicates with 16 wells seeded for each individual cell line or treatment per experiment.

Figure 10: Annexin V Apoptosis Necrosis Assay Biomolecular Mechanism.
The luminescence-based apoptosis assay measures the levels of cell surface
phosphotidylserine (PS) when the Annexin V LgBit and SmBit are in close enough
proximity to bind their complimentary units of NanoBiT® Luciferase. The florescencebased necrosis assay relies on a cell-impermeable dye that binds to intracellular DNA
only when the cell membrane structure is compromised, a hallmark of necrotic cell death.
© 2021 Promega Corporation. Reprinted with permission from Promega Corporation.
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Cell Viability Assay
GSCs were seeded and irradiated in the same manner as detailed in “Apoptosis
and Necrosis Assay.” Cell viability was measured at 14-16 days post-irradiation using the
CellTiter-Glo® 3D (CTG3D) assay. All plates equilibrated to room temperature for at
least 30 minutes prior adding the CTG3D reagent. GSCs were pipetted up and down 10
times to induce cell lysis immediately after adding the CTG3D reagent. The samples
were left in a sterile environment at room temperature for 25 minutes in the dark before
reading the luminescence viability signal using the PerkinElmer Victor X3 multimode
plate reader (Part Number 2030-0050). Raw luminescence data was converted into ATP
concentration by generating an ATP standard curve (Promega E6011). All ATP data was
normalized to the 0 Gy negative control and presented as a percent fold change from 0
Gy. Results represent an average of at least two biological replicates with 16 wells seeded
for each individual cell line or treatment per experiment.
To identify the primary cell death mechanisms activated post-XRT and post-PRT,
we treated TS543-ATRXWT and TS543-ATRXLoss GSCs 1-2 hours prior to irradiation
with either 0.05% DMSO, 10 ng/mL TNF-α (Cell Signaling Technologies 8902SC), 10
ng/mL TNF-α+10000 nM Z-VAD(OMe)-FMK (Irreversible, cell permeable pan-caspase
inhibitor; Cell Signaling Technologies 60332), 10 ng/mL TNF-α+20000 nM Nec1s
(RIPK1 inhibitor; BioVision 2535), or 10 ng/mL TNF-α+10 nM GSK2593074A76
(RIPK1/RIPK3 inhibitor; MedChemExpress HY-122909). GSCs subject to cell death
analysis were only treated once with one of the above drug combinations. However, the
media was still refreshed every 3-5 days prior to adding the CTG3D reagent.
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Figure 11: CellTiterGlo 3D Viability Assay Biomolecular Mechanism.
(A) The luciferase reaction when combined with ATP of lysed cells and oxygen creates a
luminescent signal that is used to calculate the original intracellular ATP concentration,
an indicator of the number of viable cells in culture. (B) A representative ATP standard
curve fit to a linear quadratic model to account for the curvilinear relationship between
the number of cells seeded and luminescent signal often found in 3D cell culture. © 2021
Promega Corporation. Reprinted with permission from Promega Corporation.
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Figure 12: CellTiterGlo 3D and Annexin V multiplex workflow.
The combination of the non-lytic Annexin V assay and lytic CellTiterGlo 3D assay
required a fresh media change after 72 hours to ensure that Annexin V probe induced
cytotoxicity did not occur. Annexin V timepoints included 0, 8, 16, 24, 32, 40, 48, and 72
hours after irradiation. Media changes were conducted by removing and replacing 50% of
a well’s volume with fresh media. Intracellular ATP concentrations for each well was
calculated using luminescence values generated using the luciferase based CellTiterGlo
3D reagent and an ATP standard curve. L: Luminescence. F: Florescence.
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Limiting Dilution Analysis
All GSCs were seeded at 20, 10, 5, and 1 cell/well via serial dilution at 24 hours
prior to XRT or PRT in a 96 well ultra-low attachment (ULA) plate. For LDA
experiments only, X-ray irradiations were conducted with a 320 KV, 12.5 mA beam
using the XRAD 320 at the MD Anderson Sheikh Zayed Building. Samples were placed
at a depth of 51 cm from the focus and irradiated using a field size of 20 cm x 20 cm.
Proton irradiations were conducted at the MD Anderson PTC. GSCs were imaged using
the Biotek Cytation 5 cell-imaging multimode reader equipped with Gen5 software at 4
days post-irradiation. Spheroids were defined as structures with >5 cells and diameter
>20 nm. The log fraction of non-responding wells refers to the number of wells seeded in
which spheroids did not form after irradiation; this was quantified using Extreme
Limiting Dilution Analysis (ELDA-See Figure 13).101 The online ELDA platform can be
found at https://bioinf.wehi.edu.au/software/elda/. Results represent an average of at least
2 biological replicates with 12 wells seeded at a given cell density per experiment.

Figure 13: Extreme Limiting Dilution Analysis (ELDA) workflow.
GSCs were treated with Accutase prior to seeding into 96 well ULA plates to ensure the
formation of a single cell suspension. Irradiation occurred within 24 hours of seeding and
the resulting spheroids were manually counted after 4 days. NSFF: Neurosphere
Formation Frequency. Created in Biorender.
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Results
Effects of X-Rays and Protons on ATRXLoss isogenic glioma stem cells
To investigate how the ATRX status of a glioma stem cell (GSC) impacts its
ability to self-renew after radiation therapy, we conducted extreme limiting dilution
analysis (ELDA) on TS543-ATRXWT and TS543-ATRXLoss GSCs treated with either
XRT or PRT as reported by Hu and Smyth (2009).101 The active cell frequency, denoted
here as the neurosphere formation frequency (NSFF), was calculated using a maximum
likelihood estimation. The log-log transformation fits of each condition were then
compared using a likelihood ratio test to determine whether an observed difference is
statistically significant.
We first demonstrated that the self-renewal capacity as measured by NSFF of
both TS543-ATRXWT and TS543-ATRXLoss follows an inverse relationship with the
radiation dose administered (Figure 14, Tables 1-2, 5-6). Since the validity of ELDA
data output requires that the single hit hypothesis is met, a likelihood ratio test of all the
TS543-ATRXWT data inputs in Table 1 and all the TS543-ATRXLoss data inputs in Table
4 was conducted as well as a score test for heterogeneity to ensure that the results were
consistent across different biological replicates (Table 3 and 6). The data across all
radiation doses for both TS543-ATRXWT and TS543-ATRXLoss did not reject the null
hypotheses for either of these tests, indicating that the NSFF calculated by ELDA can be
trusted. To further understand and compare the effects of ATRXLoss and ATRXWT on
GSC post-radiation self-renewal, we seeded isogenic TS543-ATRXWT and TS543ATRXLoss GSCs 24 hours prior to treatment with either 6 Gy XRT or 6 Gy PRT and
manually quantified spheroid growth after four days (Figure 15; Tables 7-12). Similar to
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the data presented in Figure 14, the null hypotheses for the single-hit hypotheses and
score tests for heterogeneity were not rejected for both TS543-ATRXWT (Table 9) and
TS543-ATRXLoss (Table 12). We determined that ATRXLoss significantly impairs GSC
self-renewal after both XRT and PRT. After comparing the ELDA calculated NSFF for
both cell lines, TS543-ATRXLoss treated with 6 Gy PRT exhibited a 1.81-fold decrease in
NSFF compared to TS543-ATRXWT. However, this same fold NSFF decrease was only
1.54 when comparing TS543-ATRXLoss and TS543-ATRXWT GSCs irradiated with 6 Gy
XRT. These results demonstrate the effectiveness of PRT over XRT in enhancing
ATRXLoss driven reduction of post-radiation GSC self-renewal.
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Figure 14: TS543 self-renewal capacity is negatively correlated with XRT dose.
ELDA plot generated after treatment with 4, 6, or 8 Gy of ionizing XRT for (A) TS543ATRXWT and (B) TS543-ATRXLoss isogenic GSCs. The solid line fits the complementary
log-log transformation of the Poisson probability formula using a generalized linear
model approach. The dotted lines indicate the upper and lower one-sided 95% confidence
intervals of this fit. The NSFF was calculated using maximum likelihood estimation. To
test whether two conditions with different NSFFs were statistically different from each
other, their log-log transformation fits were compared using a likelihood ratio test.
**p<0.01. The ELDA methodology was developed by Hu and Smyth (2009).101
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Table 1: ELDA input data for TS543-ATRXWT at 4, 6, and 8 Gy XRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
TS543-ATRXWT GSCs treated with 4, 6, and 8 Gy XRT.

Table 2: ELDA estimates of NSFF with 95% confidence intervals for TS543ATRXWT at 4, 6, and 8 Gy XRT.
Neurosphere formation frequency (NSFF) refers to the active cell frequency estimated by
ELDA with the upper and lower 95% confidence intervals. The fold reduction represents
a ratio of the NSFF calculated for TS543-ATRXLoss compared to TS543-ATRXWT GSCs
at a specific radiation dose.

Table 3: ELDA calculated adherence to the single-hit model and heterogeneity for
TS543-ATRXWT GSCs irradiated at 4, 6, and 8 Gy XRT.
Since LDA accuracy relies on the validity of the Poisson single-hit model, a likelihood
ratio test for whether the data follows a single-hit model was calculated. A p-value less
than 0.05 indicates adherence to the single-hit model. The score test for heterogeneity
determines whether assays conducted on different days exhibit a similar NSFF. A p-value
less than 0.05 indicates that different assay replicates are not heterogeneous. The slope of
the solid line also provides information on these two parameters. Slopes greater than 1
could be indicative of a multi-hit model while slopes less than 1 could indicate assay
heterogeneity or impeded ability of a sample to form neurospheres due to interference.
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Table 4: ELDA input data for TS543-ATRXLoss at 4, 6, and 8 Gy XRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
TS543-ATRXLoss GSCs treated with 4, 6, and 8 Gy XRT.

Table 5: ELDA estimates of NSFF with 95% confidence intervals for TS543ATRXLoss at 4, 6, and 8 Gy XRT.
Neurosphere formation frequency (NSFF) refers to the active cell frequency estimated by
ELDA with the upper and lower 95% confidence intervals. The fold reduction represents
a ratio of the NSFF calculated for TS543-ATRXLoss compared to TS543-ATRXWT GSCs
at a specific radiation dose.

Table 6: ELDA calculated adherence to the single-hit model and heterogeneity for
TS543-ATRXLoss GSCs irradiated at 4, 6, and 8 Gy XRT.
Since LDA accuracy relies on the validity of the Poisson single-hit model, a likelihood
ratio test for whether the data follows a single-hit model was calculated. A p-value less
than 0.05 indicates adherence to the single-hit model. The score test for heterogeneity
determines whether assays conducted on different days exhibit a similar NSFF. A p-value
less than 0.05 indicates that different assay replicates are not heterogeneous. The slope of
the solid line also provides information on these two parameters. Slopes greater than 1
could be indicative of a multi-hit model while slopes less than 1 could indicate assay
heterogeneity or impeded ability of a sample to form neurospheres due to interference.
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Figure 15: ATRXLoss impairs GSC self-renewal after both XRT and PRT.
Post-radiation neurosphere self-renewal frequency (NSFF) was measured using Extreme
Limiting Dilution Analysis (ELDA) in TS543-ATRXWT and TS543-ATRXLoss human
GSCs treated with (A) 6 Gy X-ray radiotherapy (XRT) or (B) 6 Gy Proton radiotherapy
(PRT). The solid line fits the complementary log-log transformation of the Poisson
probability formula using a generalized linear model approach. The dotted lines indicate
the upper and lower one-sided 95% confidence intervals of this fit. The NSFF was
calculated using maximum likelihood estimation. To test whether our two cell lines
exhibited significantly different NSFFs after a given dose of radiation, a chi-square test of
independence was performed. **p<0.01. The ELDA methodology was developed by Hu
and Smyth (2009).101
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Table 7: ELDA input data for TS543-ATRXWT and TS543-ATRXLoss at 6 Gy XRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
TS543-ATRXWT and TS543-ATRXLoss GSCs treated with 6 Gy XRT.

Table 8: ELDA estimates of NSFF with 95% confidence intervals for TS543ATRXWT and TS543-ATRXLoss at 6 Gy XRT.
Neurosphere formation frequency (NSFF) refers to the active cell frequency estimated by
ELDA with the upper and lower 95% confidence intervals. The fold reduction represents
a ratio of the NSFF calculated for TS543-ATRXLoss GSCs treated with 6 Gy XRT
compared to TS543-ATRXWT treated with 6 Gy XRT.

Table 9: ELDA calculated adherence to the single-hit model and heterogeneity for
TS543-ATRXWT and TS543-ATRXLoss at 6 Gy XRT.
Since LDA accuracy relies on the validity of the Poisson single-hit model, a likelihood
ratio test for whether the data follows a single-hit model was calculated. A p-value less
than 0.05 indicates adherence to the single-hit model. The score test for heterogeneity
determines whether assays conducted on different days exhibit a similar NSFF. A p-value
less than 0.05 indicates that different assay replicates are not heterogeneous. The slope of
the solid line also provides information on these two parameters. Slopes greater than 1
could be indicative of a multi-hit model while slopes less than 1 could indicate assay
heterogeneity or impeded ability of a sample to form neurospheres due to interference.
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Table 10: ELDA input data for TS543-ATRXWT and TS543-ATRXLoss at 6 Gy PRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
TS543-ATRXWT and TS543-ATRXLoss GSCs treated with 6 Gy PRT.

Table 11: ELDA estimates of NSFF with 95% confidence intervals for TS543ATRXWT and TS543-ATRXLoss at 6 Gy PRT.
Neurosphere formation frequency (NSFF) refers to the active cell frequency estimated by
ELDA with the upper and lower 95% confidence intervals. The fold reduction represents
a ratio of the NSFF calculated for TS543-ATRXLoss GSCs treated with 6 Gy PRT
compared to TS543-ATRXWT treated with 6 Gy PRT.

Table 12: ELDA calculated adherence to the single-hit model and heterogeneity for
TS543-ATRXWT and TS543-ATRXLoss at 6 Gy PRT.
Since LDA accuracy relies on the validity of the Poisson single-hit model, a likelihood
ratio test for whether the data follows a single-hit model was calculated. A p-value less
than 0.05 indicates adherence to the single-hit model. The score test for heterogeneity
determines whether assays conducted on different days exhibit a similar NSFF. A p-value
less than 0.05 indicates that different assay replicates are not heterogeneous. The slope of
the solid line also provides information on these two parameters. Slopes greater than 1
could be indicative of a multi-hit model while slopes less than 1 could indicate assay
heterogeneity or impeded ability of a sample to form neurospheres due to interference.
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Previous studies have implicated ATRX inactivation in reduced glioblastoma cell
survival after treatment with ionizing radiation therapy.48,102 Therefore, we subjected
TS543-ATRXWT and TS543-ATRXLoss GSCs to a range of XRT and PRT doses (4, 6,
and 8 Gy) and examined cell viability by quantifying the concentration of intracellular
ATP present at 14 days post-radiation using the CellTiterGlo 3D assay. When comparing
raw post-XRT and post-PRT ATP concentrations (Figure 16A), PRT significantly
reduces GSC viability regardless of ATRX mutational status. To account for the
differences in growth kinetics between TS543-ATRXWT and TS543-ATRXLoss GSCs, the
data was normalized with respect to the 0 Gy condition for each individual cell line
(Figure 16B). This normalization allowed for comparison of the changes in cell viability
exhibited in TS543-ATRXWT and TS543-ATRXLoss with increasing doses of radiation. In
addition to corroborating the PRT vs. XRT trends presented in Figure 16A, we
discovered that ATRXLoss also contributes to decreasing post-radiation GSC viability to a
higher extent than ATRXWT. These results hold true even when cells were treated with
0.05% DMSO prior to irradiation (Figure 18). To determine the correct statistical tests
for analyzing the data, cumulative frequency plots of the data were fitted to a cumulative
Gaussian curve and further analyzed for normality using the Shapiro-Wilk test (Figure
17 and 19, Tables 13 and 14). Since the data was not consistently normal, we chose to
use the non-parametric Kolmogorov-Smirnoff test to calculate statistical significance
between different conditions. Our results provide further evidence to suggest that PRT is
more effective than XRT in eliminating GSCs.
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Figure 16: ATRXLoss enhances GSC sensitivity to PRT over XRT.
Cell viability was measured using the luminescence based CellTiterGlo 3D assay at 14
days post-irradiation. (A) Intracellular ATP concentration was calculated using a
curvilinear ATP standard curve as detailed in Figure 11 and (B) normalized relative to the
0 Gy negative control. Since the data do not consistently exhibit normality across doses
and cell lines, a non-parametric approach was used to demonstrate statistical significance.
The cumulative distributions of each condition were compared using the KolmogorovSmirnov test and Holm-Sidak’s test for multiple comparisons. Outliers were removed
using ROUT (Q=1%) in Graphpad Prism 9. The mean is reported along with its upper
and lower 95% confidence intervals in black.
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Figure 17: Cumulative frequency plots of raw ATP data for TS543-ATRXWT and
TS543-ATRXLoss treated with 0, 4, 6, or 8 Gy of XRT and PRT.
The raw ATP data presented in Figure 16 was fit to the cumulative Gaussian function
using a non-weighted least squares regression model in Graphpad Prism 9. Although the
data appears normal for the combination of all radiation doses for each cell line upon
visual inspection, further analysis was conducted using the Shapiro-Wilk test, whose
results are shown in Table 13.

Table 13: Shapiro-Wilk Test for normality of raw ATP data for TS543-ATRXWT
and TS543-ATRXLoss treated with 0, 4, 6, or 8 Gy of XRT and PRT.
The Shapiro-Wilk test for normality was chosen due to its high average empirical power
compared to other tests at both small and larger sample sizes of symmetric and
asymmetric distributions.103 W and P values for each condition were calculated in
Graphpad Prism 9.
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Figure 18: ATRXLoss contributes to enhanced GSC sensitivity to PRT over XRT in
the presence of 0.05% DMSO.
Cell viability was measured using the luminescence based CellTiterGlo 3D assay at 14
days post-irradiation. (A) Intracellular ATP concentration was calculated using a
curvilinear ATP standard curve as detailed in Figure 11 and (B) normalized relative to the
0 Gy negative control. Since the data do not consistently exhibit normality across doses
and cell lines, a non-parametric approach was used to demonstrate statistical significance.
The cumulative distributions of each condition were compared using the KolmogorovSmirnov test and Holm-Sidak’s test for multiple comparisons. Outliers were removed
using ROUT (Q=1%) in Graphpad Prism 9. The mean is reported along with its upper
and lower 95% confidence intervals in black.
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Figure 19: Cumulative frequency plots of raw ATP data for TS543-ATRXWT and
TS543-ATRXLoss treated with 0, 4, 6, or 8 Gy of XRT and PRT.
The raw ATP data presented in Figure 18 was fit to the cumulative Gaussian function
using a non-weighted least squares regression model in Graphpad Prism 9. Although the
data appears to violate normality upon visual inspection, further analysis was conducted
using the Shapiro-Wilk test, whose results are shown in Table 14.

Table 14: Shapiro-Wilk Test for normality of raw ATP data for TS543-ATRXWT
and TS543-ATRXLoss treated with DMSO and 0, 4, 6, or 8 Gy of XRT and PRT.
The Shapiro-Wilk test for normality was chosen due to its high average empirical power
compared to other tests at both small and larger sample sizes of symmetric and
asymmetric distributions.103 W and P values for each condition were calculated in
Graphpad Prism 9.
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ATRXLoss drives necroptosis after proton radiotherapy
Radiation therapy is known to induce glioma cell death via apoptosis at low doses
and via necroptosis at high doses.104,105 To determine the primary mechanisms of cell
death driven by ATRXWT and ATRXLoss in human GSCs, we first imaged TS543ATRXWT and TS543-ATRXLoss via scanning electron microscopy (SEM) at 72 hours
after treatment with 0 Gy, 6 Gy XRT, or 6 Gy PRT (Figure 20). ATRXLoss GSCs
displayed more extensive membrane blebbing, swelling, and decomposition compared to
ATRXWT GSCs when irradiated with either 6 Gy XRT or PRT. all of which are
consistent with necrotic cell death. These traditionally recognized hallmarks of necrotic
cell death were more prevalent after PRT compared to XRT.106
We used the RealTime-Glo Annexin V assay to further quantify the mechanisms
of cell death present in irradiated TS543-ATRXWT and TS543-ATRXLoss GSCs. The
extent of apoptotic cell death was assessed using a Luciferase based luminescent probe to
quantify the extent of cell surface phosphatidylserine. The extent of secondary necrosis
was quantified using a florescent, membrane-impermeable dye that binds nuclear DNA
only by entering through holes in the cell membrane. To account for the baseline level of
cell death in the cell line used for each experiment, we presented the data for each
condition normalized to 0 Gy. PRT induced significantly higher apoptotic (Figure 21A)
and necrotic (Figure 21B) cell death compared to XRT in both TS543-ATRXWT and
TS543-ATRXLoss GSCs. Irradiated TS543-ATRXLoss did not exhibit a significant increase
in apoptotic cell death compared to TS543-ATRXWT. To account for the baseline signal
at the start of the experiment, we present the raw luminescence (Figure 22A; apoptosis)
and florescence (Figure 23A; necrosis) from t=0 hours to t=72 hours after irradiation
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with 8 Gy XRT or 8 Gy PRT as well as the normalized data with respect to t=0 hours
(Figure 22B and 23B). The raw data demonstrates a robust enhancement of apoptotic
and necrotic cell death in TS543-ATRXLoss compared to TS543-ATRXWT. Although this
trend is recapitulated in the normalized apoptosis data, there are no significant differences
between any of the conditions in the normalized necrosis data. This could be due to the
data’s high standard deviation; therefore, presenting the median and interquartile range
might hold better predictive value of the data’s central tendency in this case.
Nevertheless, our data demonstrates the potential benefits of PRT over XRT in inducing
apoptotic and necrotic cell death to eliminate ATRXLoss GSCs.
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Figure 20: Scanning Electron Microscopy (SEM) images of irradiated TS543ATRXWT and TS543-ATRXLoss.
Representative SEM images of TS543-ATRXWT and TS543-ATRXLoss.irradiated with 0
Gy, 6 Gy XRT, or 6 Gy PRT. Magnification of the 0 Gy images was 10000x.
Magnification of the 6 Gy XRT and 6 Gy PRT images was 8000x. The red arrows
indicate membrane swelling and permeabilization, two indicators of necrotic cell death.
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Figure 21: ATRXLoss enhances radiation-induced necrotic cell death over apoptotic
cell death compared to ATRXWT in human GSCs.
TS543-ATRXWT and TS543-ATRXLoss GSCs were subject to 2, 4, 6, and 8 Gy XRT or
PRT. Cell death was measured using the RealTime-Glo Annexin V (A) luminescencebased apoptosis assay at 8 hours post-irradiation and (B) florescent-based necrosis assay
at 72 hours post-irradiation according to the workflow detailed in Figure 12. All
measurements for each cell line were normalized to their respective 0 Gy negative
controls. For this figure only, XRT was conducted using the XRAD 320 at MD Anderson
Sheikh Zayed Building. P-values were calculated using the Kolmogorov-Smirnov test
and Holm-Sidak’s test for multiple comparisons. Outliers were removed using ROUT
(Q=1%) in Graphpad Prism 9. The mean is reported along with its upper and lower 95%
confidence intervals in black.
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Figure 22: Proton radiotherapy significantly enhances apoptotic cell death in both
ATRXWT and ATRXLoss GSCs compared to X-ray radiotherapy.
TS543-ATRXWT and TS543-ATRXLoss GSCs were subject to 8 Gy XRT or PRT. (A)
Raw RealTime-Glo Annexin V luminescent output measurements were taken at t=0, 12,
24, 48, and 72 hours after irradiation. (B) All measurements for each condition were
normalized to the luminescence measured at t=0 hours. P-values were calculated using
the Kolmogorov-Smirnov test and Holm-Sidak’s test for multiple comparisons. Outliers
were removed using ROUT (Q=1%) in Graphpad Prism 9. The mean is reported along
with its upper and lower 95% confidence intervals in black.
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Figure 23: ATRXLoss significantly enhances radiation induced necrotic cell death
over ATRXWT in TS543 GSCs.
TS543-ATRXWT and TS543-ATRXLoss GSCs were subject to 8 Gy XRT or PRT.
(A) Raw RealTime-Glo Annexin V florescent output measurements were taken at t=0,
12, 24, 48, and 72 hours after irradiation. (B) All measurements for each condition were
normalized to the luminescence measured at t=0 hours. P-values were calculated using
the Kolmogorov-Smirnov test and Holm-Sidak’s test for multiple comparisons. Outliers
were removed using ROUT (Q=1%) in Graphpad Prism 9. The mean is reported along
with its upper and lower 95% confidence intervals in black.
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The formation of the RIP1/RIP3 necrosome is required for necroptotic cell death.
However, cells can be rescued from necroptosis by pharmacologically inhibiting RIP1 or
RIP3, especially with the selective RIP1 inhibitor Nec-1s.104,107 To further characterize
the mechanisms by which ATRXLoss promotes cell death, we measured post-radiation cell
viability in TS543-ATRXWT and TS543-ATRXLoss GSCs when combined with TNF-α
and irreversible chemical inhibitors known to impair apoptosis (Z-VAD(OMe)-FMK;
pan-caspase inhibitor) and necroptosis (RIP1 inhibitor Nec1s; RIP1/RIP3 inhibitor
GSK2593074A). GSCs were treated with TNF-α before radiation to stimulate extrinsic
necroptosis. Z-VAD(OMe)-FMK was administered to more accurately simulate GBM
therapeutic resistance due to GBM upregulation of anti-apoptotic proteins (Bcl-w, Bcl-2,
and Bcl-xL) and downregulation of pro-apoptotic proteins (Bax, Bak, Bok, and
NOXA).108 Although TS543-ATRXWT GSCs are highly XRT resistant, their viability
increases substantially when pre-treated with RIPK1/RIPK3 inhibitor GSK2593074A
(Figure 24A). This trend disappeared after normalization of the data to its 0 Gy (Figure
24B), possibly due to TS543-ATRXWT radioresistance. On the other hand, TS543ATRXLoss exhibits heavy resistance to all pharmacological inhibitors added (Figure
25A), but a dependency on the necroptotic cell death pathway as demonstrated by the 0
Gy normalized data (Figure 25B). These trends are recapitulated when TS543-ATRXWT
(Figure 26) and TS543-ATRXLoss (Figure 27) are treated with PRT. As demonstrated in
Figure 16, TS543-ATRXWT and TS543-ATRXLoss are heavily sensitized to PRT over
XRT, even in the presence of the RIPK1/RIPK3 inhibitor GSK2593074A (Figure 28).
Our data demonstrate that ATRXWT GSCs heavily rely on the formation of the
RIPK1/RIPK3 necrosome for radiation induced cell death.
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Figure 24: ATRXWT drives post-XRT cell death via apoptosis and necroptosis.
TS543-ATRXWT was treated with combinations of 0.05% DMSO, 10 ng/mL TNF-α to
activate extrinsic apoptosis, 10 uM Z-VAD(OMe)-FMK (pan-caspase inhibitor), 20 uM
Necrostatin-1s (RIPK1 inhibitor), and 10 nM GSK074 (RIPK1/RIPK3 inhibitor) prior to
treatment with 0, 4, and 8 Gy XRT. Raw ATP values are presented in (A) while
normalized ATP values relative to each condition’s respective 0 Gy control are presented
in (B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s
test for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 25: ATRXLoss drives post-XRT cell death primarily via necroptosis.
TS543-ATRXLoss was treated with combinations of 0.05% DMSO, 10 ng/mL TNF-α to
activate extrinsic apoptosis, 10 uM Z-VAD(OMe)-FMK (pan-caspase inhibitor), 20 uM
Necrostatin-1s (RIPK1 inhibitor), and 10 nM GSK074 (RIPK1/RIPK3 inhibitor) prior to
treatment with 0, 4, and 8 Gy XRT. Raw ATP values are presented in (A) while
normalized ATP values relative to each condition’s respective 0 Gy control are presented
in (B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s
test for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 26: ATRXWT drives post-XRT cell death via apoptosis and necroptosis.
TS543-ATRXWT was treated with combinations of 0.05% DMSO, 10 ng/mL TNF-α to
activate extrinsic apoptosis, 10 uM Z-VAD(OMe)-FMK (pan-caspase inhibitor), 20 uM
Necrostatin-1s (RIPK1 inhibitor), and 10 nM GSK074 (RIPK1/RIPK3 inhibitor) prior to
treatment with 0, 4, and 8 Gy XRT. Raw ATP values are presented in (A) while
normalized ATP values relative to each condition’s respective 0 Gy control are presented
in (B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s
test for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 27: ATRXLoss does not significantly drive PRT induced necroptosis.
TS543-ATRXLoss was treated with combinations of 0.05% DMSO, 10 ng/mL TNF-α to
activate extrinsic apoptosis, 10 uM Z-VAD(OMe)-FMK (pan-caspase inhibitor), 20 uM
Necrostatin-1s (RIPK1 inhibitor), and 10 nM GSK074 (RIPK1/RIPK3 inhibitor) prior to
treatment with 0, 4, and 8 Gy XRT. Raw ATP values are presented in (A) while
normalized ATP values relative to each condition’s respective 0 Gy control are presented
in (B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s
test for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 28: Proton radiotherapy significantly decreases GSC viability independent of
ATRX status compared to ionizing X-ray radiotherapy.
Data for irradiated TS543-ATRXWT and TS543-ATRXLoss GSCs treated with either 10
ng/mL TNF-α or 10 ng/mL TNF-α combined with 10 uM Z-VAD(OMe)-FMK (pancaspase inhibitor) and 10 nM GSK074 (RIPK1/RIPK3 inhibitor).
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Effects of X-rays and Protons on IDH1R132H isogenic glioma stem cells
Considering the prevalence of IDH1R132H in patients with low-grade gliomas and
secondary glioblastomas,20 we investigated how IDH1R132H affects the sensitization of
human GSCs to PRT compared to XRT using the isogenic doxycycline activated cell
lines MGG18-IDH1WT and MGG18-IDH1R132H. Following the same ELDA methodology
as described above for TS543 GSCs, we quantified an inverse relationship between NSFF
and radiation dose for MGG18-IDH1WT and MGG18-IDH1R132H after treatment with
XRT (Figure 29, Tables 15-20) and PRT (Figure 30, Tables 21-26). MGG18-IDH1R132H
exhibited a 2.12-fold decrease in NSFF compared to MGG18-IDH1WT irradiated with 6
Gy XRT. MGG18-IDH1R132H exhibited a 2.05-fold decrease compared to MGG18IDH1WT irradiated with 6 Gy PRT (Figure 31, Tables 27-32). These results suggest that
PRT is equally as effective as XRT in impairing self-renewal in the MGG18 GSC line.
In addition to its established presence as a positive prognostic marker for patients
with low-grade gliomas and glioblastomas, IDH1R132H is known to promote radiationinduced GBM cell death via the production of the oncometabolite 2-Hydroxyglutarate (2HG).32 To investigate the effects of IDH1R132H on GSC radiosensitivity, we exposed
MGG18-IDH1WT and MGG18-IDH1R132H with 0, 4, 6, and 8 Gy XRT or PRT and
quantified the intracellular ATP concentration using the CellTiterGlo 3D assay as
described previously at 14 days post-irradiation. In the raw ATP data, MGG18IDH1R132H treated with PRT demonstrates lower cell viability than MGG18-IDH1WT
GSCs (Figure 32A). However, this might be misleading since the MGG18-IDH1R132H 0
Gy negative controls independently demonstrated differences in viability. After
normalizing each condition to its 0 Gy control, no statistically significant differences in
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post-XRT or post-PRT cell viability between MGG18-IDH1WT and MGG18-IDH1R132H
were observed except at 8 Gy PRT, at which MGG18-IDH1R132H exhibited higher
viability than MGG18-IDH1WT (Figure 32B). Our data also demonstrates that while
MGG18-IDH1R132H GSCs do not exhibit noticeable differences in viability when
comparing XRT to PRT, MGG18-IDH1WT GSCs are more sensitized to PRT over XRT
at 8 Gy. The cumulative frequency plots and Shapiro-Wilk test results led us to analyze
statistical significance using the same non-parametric Kolmogorov-Smirnoff approach
that was conducted for the isogenic TS543-ATRXWT and TS543-ATRXLoss cell viability
data (Figure 33, Table 33). A closer analysis of the cell death mechanisms activated
from 0-72 hours after irradiation with 8 Gy XRT compared to 8 Gy PRT revealed a
heightened increase in apoptotic cell death in both MGG18-IDH1WT and MGG18IDH1R132H treated with 8 Gy PRT (Figure 34A). However, only MGG18-IDH1R132H
exhibited statistically significant increases in necrotic cell death after 8 Gy PRT
compared to 8 Gy XRT (Figure 34B).
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Figure 29: MGG18 self-renewal is inversely related to XRT dose delivered.
ELDA plot generated after treatment with 2, 4, 6, or 8 Gy of ionizing XRT for (A)
MGG18-IDH1WT and (B) MGG18-IDH1R132H isogenic GSCs.
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Table 15: ELDA input data for MGG18-IDH1WT at 2, 4, 6, and 8 Gy XRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
MGG18-IDH1WT GSCs treated with 2, 4, 6, and 8 Gy XRT.

Table 16: ELDA estimates of NSFF with 95% confidence intervals for MGG18IDH1WT at 2, 4, 6, and 8 Gy XRT.
Neurosphere formation frequency refers to the active cell frequency estimated by ELDA
with the upper and lower 95% confidence intervals. The fold reduction represents a ratio
of the NSFF calculated for MGG18-IDH1R132H compared to MGG18-IDH1WT GSCs at a
given radiation dose.

Table 17: ELDA calculated adherence to the single-hit model and heterogeneity for
MGG18-IDH1WT GSCs irradiated at 2, 4, 6, and 8 Gy XRT.
A likelihood ratio test with p<0.05 indicates the probability that the single-hit model is
accurate. A score test with p<0.05 likely indicates that assay replicates completed at
different times are not heterogeneous.
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Table 18: ELDA input data for MGG18-IDH1R132H at 2, 4, 6, and 8 Gy XRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
MGG18-IDH1R132H GSCs treated with 2, 4, 6, and 8 Gy XRT.

Table 19: ELDA estimates of NSFF with 95% confidence intervals for MGG18IDH1R132H at 2, 4, 6, and 8 Gy XRT.
Neurosphere formation frequency refers to the active cell frequency estimated by ELDA
with the upper and lower 95% confidence intervals. The fold reduction represents a ratio
of the NSFF calculated for MGG18-IDH1R132H compared to MGG18-IDH1WT GSCs at a
given radiation dose.

Table 20: ELDA calculated adherence to the single-hit model and heterogeneity for
MGG18-IDH1R132H GSCs irradiated at 2, 4, 6, and 8 Gy XRT.
A likelihood ratio test with p<0.05 indicates the probability that the single-hit model is
accurate. A score test with p<0.05 likely indicates that assay replicates completed at
different times are not heterogeneous.
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Figure 30: MGG18 self-renewal is inversely related to PRT dose delivered.
ELDA plot generated after treatment with 2, 4, or 6 Gy PRT for (A) MGG18-IDH1WT
and (B) MGG18-IDH1R132H isogenic GSCs.
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Table 21: ELDA input data for MGG18-IDH1WT at 2, 4, and 6 Gy PRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
MGG18-IDH1WT GSCs treated with 2, 4, or 6 Gy PRT.

Table 22: ELDA estimates of NSFF with 95% confidence intervals for MGG18IDH1WT at 2, 4, and 6 Gy PRT.
Neurosphere formation frequency refers to the active cell frequency estimated by ELDA
with the upper and lower 95% confidence intervals. The fold reduction represents a ratio
of the NSFF calculated for MGG18-IDH1R132H compared to MGG18-IDH1WT GSCs at a
given radiation dose.

Table 23: ELDA calculated adherence to the single-hit model and heterogeneity for
MGG18-IDH1WT GSCs irradiated at 2, 4, and 6 Gy PRT.
A likelihood ratio test with p<0.05 indicates the probability that the single-hit model is
accurate. A score test with p<0.05 likely indicates that assay replicates completed at
different times are not heterogeneous.
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Table 24: ELDA input data for MGG18-IDH1R132H at 2, 4, and 6 Gy PRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
MGG18-IDH1R132H GSCs treated with 2, 4, and 6 Gy PRT.

Table 25: ELDA estimates of NSFF with 95% confidence intervals for MGG18IDH1R132H at 2, 4, and 6 Gy PRT.
Neurosphere formation frequency refers to the active cell frequency estimated by ELDA
with the upper and lower 95% confidence intervals. The fold reduction represents a ratio
of the NSFF calculated for MGG18-IDH1R132H compared to MGG18-IDH1WT GSCs at a
given radiation dose.

Table 26: ELDA calculated adherence to the single-hit model and heterogeneity for
MGG18-IDH1R132H GSCs irradiated at 2, 4, and 6 Gy PRT.
A likelihood ratio test with p<0.05 indicates the probability that the single-hit model is
accurate. A score test with p<0.05 likely indicates that assay replicates completed at
different times are not heterogeneous.
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Figure 31: IDH1R132H impairs GSC self-renewal after both XRT and PRT.
Post-radiation neurosphere self-renewal was measured using Extreme Limiting Dilution
Analysis (ELDA) in MGG18-IDH1WT and MGG18-IDH1R132H human GSCs treated with
(A) 6 Gy X-ray radiotherapy (XRT) and (B) 6 Gy Proton radiotherapy (PRT).
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Table 27: ELDA input data for MGG18-IDH1WT and MGG18-IDH1R132H at 6 Gy
XRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
MGG18-IDH1WT and MGG18-IDH1R132H GSCs treated with 6 Gy XRT.

Table 28: ELDA estimates of NSFF with 95% confidence intervals for MGG18IDH1WT and MGG18-IDH1R132H at 6 Gy XRT.
Neurosphere formation frequency refers to the active cell frequency estimated by ELDA
with the upper and lower 95% confidence intervals. The fold reduction represents a ratio
of the NSFF calculated for MGG18-IDH1R132H GSCs treated with 6 Gy XRT compared
to MGG18-IDH1WT treated with 6 Gy XRT.

Table 29: ELDA calculated adherence to the single-hit model and heterogeneity for
TS543-ATRXWT and TS543-ATRXLoss at 6 Gy XRT.
Since LDA accuracy relies on the validity of the Poisson single-hit model, a likelihood
ratio test for whether the data follows a single-hit model was calculated. A p-value less
than 0.05 indicates adherence to the single-hit model. The score test for heterogeneity
determines whether assays conducted on different days exhibit a similar NSFF. A p-value
less than 0.05 indicates that different assay replicates are not heterogeneous. The slope of
the solid line also provides information on these two parameters. Slopes greater than 1
could be indicative of a multi-hit model while slopes less than 1 could indicate assay
heterogeneity or impeded ability of a sample to form neurospheres due to interference.

71

Table 30: ELDA input data for MGG18-IDH1WT and MGG18-IDH1R132H at 6 Gy
PRT.
The raw data of positive cultures, indicating successful neurosphere formation, for
MGG18-IDH1WT and MGG18-IDH1R132H GSCs treated with 6 Gy PRT.

Table 31: ELDA estimates of NSFF with 95% confidence intervals for MGG18IDH1WT and MGG18-IDH1R132H at 6 Gy PRT.
Neurosphere formation frequency refers to the active cell frequency estimated by ELDA
with the upper and lower 95% confidence intervals. The fold reduction represents a ratio
of the NSFF calculated for MGG18-IDH1R132H GSCs treated with 6 Gy XRT compared
to MGG18-IDH1WT treated with 6 Gy PRT.

Table 32: ELDA calculated adherence to the single-hit model and heterogeneity for
MGG18-IDH1WT and MGG18-IDH1R132H at 6 Gy PRT.
Since LDA accuracy relies on the validity of the Poisson single-hit model, a likelihood
ratio test for whether the data follows a single-hit model was calculated. A p-value less
than 0.05 indicates adherence to the single-hit model. The score test for heterogeneity
determines whether assays conducted on different days exhibit a similar NSFF. A p-value
less than 0.05 indicates that different assay replicates are not heterogeneous. The slope of
the solid line also provides information on these two parameters. Slopes greater than 1
could be indicative of a multi-hit model while slopes less than 1 could indicate assay
heterogeneity or impeded ability of a sample to form neurospheres due to interference.

72

Figure 32: IDH1R132H does not enhance GSC sensitivity to PRT over XRT.
Cell viability was measured using the luminescence based CellTiterGlo 3D assay at 14
days post-irradiation. (A) Intracellular ATP concentration was calculated using a
curvilinear ATP standard curve as detailed in Figure 11 and (B) normalized relative to the
0 Gy negative control. Since the data do not consistently exhibit normality across doses
and cell lines, a non-parametric approach was used to demonstrate statistical significance.
The cumulative distributions of each condition were compared using the KolmogorovSmirnov test and Holm-Sidak’s test for multiple comparisons. Outliers were removed
using ROUT (Q=1%) in Graphpad Prism 9. The mean is reported along with its upper
and lower 95% confidence intervals in black.
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Figure 33: Cumulative frequency plots of raw intracellular ATP data for MGG18IDH1WT and MGG18-IDH1R132H treated with 0, 4, 6, or 8 Gy of XRT and PRT.
The raw ATP data presented in Figure 32 was fit to the cumulative Gaussian function
using a non-weighted least squares regression model in Graphpad Prism 9. Although the
data appears to violate normality upon visual inspection, further analysis was conducted
using the Shapiro-Wilk test, whose results are shown in Table 33.

Table 33: Shapiro-Wilk Test for normality of raw ATP data for MGG18-IDH1WT
and MGG18-IDH1R132H treated with 0, 4, 6, or 8 Gy of XRT and PRT.
The Shapiro-Wilk test for normality was chosen due to its high average empirical power
compared to other tests at both small and larger sample sizes of symmetric and
asymmetric distributions.103 W and P values for each condition were calculated in
Graphpad Prism 9.
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Figure 34: Protons increase apoptotic cell death in both IDH1WT and IDH1R132H
GSCs, but only necrotic cell death in IDH1R132H GSCs compared to X-rays.
MGG18-IDH1WT and MGG18-IDH1R132H GSCs were subject to 8 Gy XRT or PRT.
RealTime-Glo Annexin V (A) luminescence (apoptosis) and (B) florescence (necrosis)
output measurements were taken at t=0, 12, 24, 48, and 72 hours after irradiation. All
measurements for each condition were normalized to the luminescence measured at t=0
hours. P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s
test for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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IDH1R132H drives radiosensitivity in the context of ATRXLoss
Ivosidenib is a newly developed chemical inhibitor selective for arginine 132 of
cytosolic IDH1 that significantly reduces the production of 2-HG. This inhibitor was first
shown to impair the growth of AML blast cells in vitro as well as promoted their
differentiation.109 As a result of promising preclinical data, Ivosidenib is currently in two
independent phase I clinical trials for patients with low-grade gliomas.109-111 Due to the
combined presence of IDH1R132H and ATRX inactivating mutations in patients with
astrocytoma,11 we investigated how IDH1R132H impacts the cell death mechanisms that
drive radiosensitivity in ATRXLoss GSCs that we previously discovered by combining
Ivosidenib with radiation therapy. To determine the effects of this combination therapy
on cell viability, we first treated the IDH1R132H/ATRXLoss GS522 GSC line with
Ivosidenib 1-2 hours prior to 4-10 Gy XRT or PRT. Following previously described
methods, we quantified the intracellular ATP concentration at 14 days post-irradiation
using the CellTiterGlo 3D assay. Inhibiting IDH1R132H with Ivosidenib prior to XRT does
not demonstrate consistent statistically significant effects on GS522 post-radiation
viability (Figure 35). Although the effects are similar for GS522s treated with Ivosidenib
and PRT, these cells exhibit slight radioresistance at higher PRT doses, especially at 8 Gy
(Figure 36). Consistent with isogenic MGG18 and TS543 GSCs, GS522 exhibits
profound sensitivity to PRT over XRT in both the raw ATP and 0 Gy normalized data
(Figure 37). Using the RealTime-Glo Annexin V apoptosis and necrosis assay protocol
detailed previously, we discovered that combining Ivosidenib with either 6 Gy XRT
(Figures 38-39) or 6 Gy PRT (Figures 40-41) impairs both apoptotic and necrotic cell
death in an Ivosidenib dose-dependent manner.
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Figure 35: Combining IDH1R132H inhibitors with XRT does not significantly reduce
viability in ATRXLoss/IDH1R132H GSCs.
GS522 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 4, 6, 8, or 10 Gy XRT. Cell viability was measured at 14 days
post-irradiation using the CellTiterGlo 3D assay. The raw intracellular ATP
concentrations measured are displayed in (A) while the normalized data relative to 0 Gy
are displayed in (B). P-values were calculated using the Kolmogorov-Smirnov test and
Holm-Sidak’s test for multiple comparisons. Outliers were removed using ROUT
(Q=1%) in Graphpad Prism 9. The mean is reported along with its upper and lower 95%
confidence intervals in black.
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Figure 36: Combining IDH1R132H inhibitors with PRT slightly increases postradiation viability in ATRXLoss/IDH1R132H GSCs.
GS522 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 4, 6, 8, or 10 Gy PRT. Cell viability was measured at 14 days
post-irradiation using the CellTiterGlo 3D assay. The raw intracellular ATP
concentrations measured are displayed in (A) while the normalized data relative to 0 Gy
are displayed in (B). P-values were calculated using the Kolmogorov-Smirnov test and
Holm-Sidak’s test for multiple comparisons. Outliers were removed using ROUT
(Q=1%) in Graphpad Prism 9. The mean is reported along with its upper and lower 95%
confidence intervals in black.
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Figure 37: Proton radiotherapy significantly decreases the viability of GS522
(ATRXLoss/IDH1R132H) GSCs compared to ionizing X-ray radiotherapy.
Cell viability was measured at 14 days after irradiation with 0, 4, 6, 8, or 10 Gy XRT or
PRT using the CellTiterGlo 3D assay. The raw intracellular ATP concentrations
measured are displayed in (A) while the normalized data relative to 0 Gy are displayed in
(B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test
for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 38: Combining IDH1R132H inhibitors with XRT significantly decreases
apoptotic cell death in ATRXLoss/IDH1R132H GSCs.
GS522 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 6 Gy XRT. Apoptotic cell death was measured using the Annexin
V luminescence assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours
post irradiation. The raw intracellular ATP concentrations collected are presented in (A)
while the data normalized to t=0 hours for each Ivosidenib concentration is presented in
(B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test
for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 39: Combining IDH1R132H inhibitors with XRT significantly decreases
necrotic cell death in ATRXLoss/IDH1R132H GSCs.
GS522 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 6 Gy XRT. Necrotic cell death was measured using the Annexin V
necrosis assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours post
irradiation. The raw intracellular ATP concentrations collected are presented in (A) while
the data normalized to t=0 hours for each Ivosidenib concentration is presented in (B). Pvalues were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test for
multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad Prism
9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 40: Combining IDH1R132H inhibitors with PRT significantly decreases
apoptotic cell death in ATRXLoss/IDH1R132H GSCs.
GS522 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 6 Gy PRT. Apoptotic cell death was measured using the Annexin
V luminescence assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours
post irradiation. The raw intracellular ATP concentrations collected are presented in (A)
while the data normalized to t=0 hours for each Ivosidenib concentration is presented in
(B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test
for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.

82

Figure 41: Combining IDH1R132H inhibitors with PRT significantly decreases
necrotic cell death in ATRXLoss/IDH1R132H GSCs.
GS522 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 6 Gy PRT. Necrotic cell death was measured using the Annexin V
necrosis assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours post
irradiation. The raw intracellular ATP concentrations collected are presented in (A) while
the data normalized to t=0 hours for each Ivosidenib concentration is presented in (B). Pvalues were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test for
multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad Prism
9. The mean is reported along with its upper and lower 95% confidence intervals.
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IDH1R132H drives radioresistance in the context of wild-type ATRX
In addition to identifying molecular markers for diagnosing astrocytomas, the
World

Health

Organization

(WHO)

designated

oligodendrogliomas

as

ATRXWT/IDH1R132H tumors in 2016.11 We treated TS603s, a ATRXWT/IDH1R132H human
GSC line, with combined Ivosidenib and radiation therapy to determine how the intact
ATRX protein and IDH1R132H impact GSC radiosensitivity. When pre-treating cells 1-2
hours prior to radiation therapy, Ivosidenib improves TS603 sensitivity to both XRT
(Figure 42) and PRT (Figure 43) in a dose-dependent manner, as indicated by both raw
and normalized ATP data relative to 0 Gy obtained using the CellTiterGlo 3D viability
assay. To quantify the cell death mechanisms present in TS603 GSCs treated with
radiation therapy and Ivosidenib, we used the RealTime-Glo Annexin V apoptosis and
necrosis assay to measure apoptotic and necrotic cell death from 0-72 hours after
irradiation. After analysis of the raw data, we discovered that combining Ivosidenib with
8 Gy XRT suppresses apoptotic and necrotic cell death in TS603 GSCs (Figures 44A
and 45A). To account for the differences in luminescent and florescent signal at the
beginning of the experiment, we normalized the data for each Ivosidenib concentration to
0 hours (Figures 44B and 45B). Normalizing the data demonstrates that Ivosidenib
increases apoptotic and necrotic cell death in TS603s subject to 8 Gy XRT. Although
similar trends were found in TS603 GSCs treated with combined 8 Gy PRT and
Ivosidenib, they were not found to be statistically significant (Figures 46 and 47). Our
results suggest that IDH1R132H promotes radiosensitivity in ATRXLoss GSCs, but
radioresistance in ATRXWT GSCs. However, confirming these results by using limiting
dilution analysis (ELDA) will be critical in solidifying the validity of these results.
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Figure 42: Combining IDH1R132H inhibitors with XRT significantly reduces viability
in ATRXWT/IDH1R132H GSCs.
TS603 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 4, 6, 8, or 10 Gy XRT. Cell viability was measured at 14 days
post-irradiation using the CellTiterGlo 3D assay. The raw intracellular ATP
concentrations measured are displayed in (A) while the normalized data relative to 0 Gy
are displayed in (B). P-values were calculated using the Kolmogorov-Smirnov test and
Holm-Sidak’s test for multiple comparisons. Outliers were removed using ROUT
(Q=1%) in Graphpad Prism 9. The mean is reported along with its upper and lower 95%
confidence intervals in black.
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Figure 43: Combining IDH1R132H inhibitors with PRT significantly decreases postradiation viability in ATRXWT/IDH1R132H GSCs.
TS603 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 4, 6, 8, or 10 Gy PRT. Cell viability was measured at 14 days
post-irradiation using the CellTiterGlo 3D assay. The raw intracellular ATP
concentrations measured are displayed in (A) while the normalized data relative to 0 Gy
are displayed in (B). P-values were calculated using the Kolmogorov-Smirnov test and
Holm-Sidak’s test for multiple comparisons. Outliers were removed using ROUT
(Q=1%) in Graphpad Prism 9. The mean is reported along with its upper and lower 95%
confidence intervals in black.
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Figure 44: Combining IDH1R132H inhibitors with XRT significantly increases
apoptotic cell death in ATRXWT/IDH1R132H GSCs.
TS603 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 8 Gy XRT. Apoptotic cell death was measured using the Annexin
V luminescence assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours
post irradiation. The raw intracellular ATP concentrations collected are presented in (A)
while the data normalized to t=0 hours for each Ivosidenib concentration is presented in
(B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test
for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 45: Combining IDH1R132H inhibitors with XRT significantly increases
necrotic cell death in ATRXWT/IDH1R132H GSCs.
TS603 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 8 Gy XRT. Necrotic cell death was measured using the Annexin V
necrosis assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours post
irradiation. The raw intracellular ATP concentrations collected are presented in (A) while
the data normalized to t=0 hours for each Ivosidenib concentration is presented in (B). Pvalues were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test for
multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad Prism
9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 46: Combining IDH1R132H inhibitors with PRT slightly, but not significantly
increases apoptotic cell death in ATRXWT/IDH1R132H GSCs.
TS603 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 8 Gy PRT. Apoptotic cell death was measured using the Annexin
V luminescence assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours
post irradiation. The raw intracellular ATP concentrations collected are presented in (A)
while the data normalized to t=0 hours for each Ivosidenib concentration is presented in
(B). P-values were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test
for multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad
Prism 9. The mean is reported along with its upper and lower 95% confidence intervals.
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Figure 47: Combining IDH1R132H inhibitors with PRT does not significantly impact
necrotic cell death in ATRXWT/IDH1R132H GSCs.
TS603 GSCs were subject to treatment with Ivosidenib (IDH1R132H inhibitor) 2 hours
prior to treatment with 8 Gy XRT. Necrotic cell death was measured using the Annexin V
necrosis assay with measurements taken at t=0, 8, 16, 24, 32, 40, 48, and 72 hours post
irradiation. The raw intracellular ATP concentrations collected are presented in (A) while
the data normalized to t=0 hours for each Ivosidenib concentration is presented in (B). Pvalues were calculated using the Kolmogorov-Smirnov test and Holm-Sidak’s test for
multiple comparisons. Outliers were removed using ROUT (Q=1%) in Graphpad Prism
9. The mean is reported along with its upper and lower 95% confidence intervals.

90

Discussion
We demonstrated that ATRXLoss impairs GSC self-renewal and viability by
increasing radiation induced apoptotic and necrotic cell death compared to ATRXWT. The
radiosensitization driven by ATRX inactivation was profoundly increased in GSCs
treated with PRT compared to XRT. This is consistent with results presented by Alan
Mitteer et al (2015) that demonstrate enhanced GSC toxicity after PRT compared to XRT
due to the elevated reactive oxygen species production in the cell.95 With respect to
ATRXLoss in GSCs, we corroborate previous work conducted by Koschmann et al (2016)
that identified ATRXLoss sensitized GBM cells to ionizing radiation by impairing DSB
repair activity via NHEJ, as demonstrated by decreased DNA-PKCs phosphorylation.112
The results of our cell viability assays are also in line with the consensus that PRT
exhibits a higher relative biological effectiveness (RBE) when compared to XRT,
especially with regards to cell death.113,114 Although clinical PRT is assigned a consistent
RBE of 1.1 by radiation oncologists, the RBE of PRT is variable.115,116 The distal dose
fall off regions of the spread-out Bragg peak (SOBP) are especially well known to exhibit
higher RBE values than the middle of the SOBP. Our irradiations were conducted in the
middle of the SOBP to ensure that the entire GSC spheroid received a uniform dose and
for its clinical relevance since most of the tumor volume is located within the SOBP.
However, the exact RBE at each point of the SOBP is dependent on the LET and other
biological factors, including tumor genotype, endpoint, and tumor microenvironment.115
Our results demonstrate that ATRXLoss enhances the cytotoxicity of radiation therapy in
GSCs to a higher extent after PRT compared to XRT. This suggests that PRT might serve
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as a more effective treatment modality to eliminate GSCs and impair secondary tumor
recurrence in patients with ATRXLoss tumors.
Although previous studies suggest that ATRXLoss gliomas might exhibit
radioresistance due to their heightened proliferation and ability to maintain telomere
length via the alternative lengthening of telomeres (ALT) phenotype,50,117 we
demonstrated that ATRXLoss drives radiosensitization via PRT induced necrosis. Our
work corroborates that of Eid et. al (2015), who proved that ATRXLoss increases the
proportion of necrotic cells in vitro via flow cytometry using 8-MG-BA glioma as a
model system.118 Although RIPK3 has been previously shown by Lee et al. (2013) to
phosphorylate the ATRX transcriptional co-activator DAXX at Ser-668, thereby allowing
DAXX to leave the nucleus in rat retinal ganglion cells, we are the first to establish a
connection between ATRXWT and RIPK1/RIPK3 mediated necroptosis in GSCs.119 This
gives rise to the possibility that the ATRX-DAXX complex phosphorylates RIPK3 in the
nucleus; however, further investigation is required to confirm this proposed mechanism.
Alongside our results demonstrating ATRXLoss driven radiosensitivity in isogenic
human GSCs, we provide evidence to support the conclusion that PRT significantly
enhances apoptosis and necrosis in isogenic IDH1R132H GSCs compared to XRT.
Although IDH1R132H suppresses post-radiation GSC self-renewal after XRT and PRT, we
did not exhibit any significant differences in cell viability between IDH1WT and
IDH1R132H after radiation therapy. These results are in contrast to previous reports
identifying IDH1R132H as a key radiosensitizing agent in glioblastoma.120-122 However, a
consensus on whether IDH1R132H promotes sensitivity or resistance to radiation therapy
has not yet been conclusively defined. Several groups have demonstrated that IDH1R132H
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isogenically induces radiosensitization in different cancer cell lines (HCT116 and
U87MG) by upregulating the production of dsDNA damage response proteins gH2AX
and 53BP1 as well as by suppressing 3D spheroid growth.32,34,120,121 These results
corroborate the clinical findings that patients with IDH mutant gliomas tend to exhibit
higher

median

survival

than

those

with

wtIDH

tumors.20

The

enhanced

chemoradioresistance of glioma stem cells might contribute to the non-significant
differences in cell viability that we observed. Verifying the presence of the IDH1R132H
experimentally via western blot or by quantifying the intracellular concentration of 2-HG
before and after radiation therapy for the isogenic MGG18 GSC line could provide
valuable insight into these experimental findings.
Finally, we established that IDH1R132H promotes radiosensitivity in ATRXLoss
GSCs and promotes radioresistance in ATRXWT GSCs, as demonstrated in experiments
combining radiation therapy with the selective IDH1R132H inhibitor Ivosidenib. Although
IDH1R132H inhibitors are currently seeing success in clinical trials when administered
independently,110,111,123 our results demonstrate that combining them with radiation
therapy in real time could be non-advantageous and possibly dangerous for patients with
astrocytomas (ATRXLoss and IDH mutant). We corroborated the findings presented by
Molenaar et al (2015), who demonstrated that combining AGI-5198 (another selective
IDH1R132H inhibitor) with ionizing radiation in U251 glioblastoma cells increases
clonogenic survival and decreases ROS levels in vitro.124 Although many studies have
focused on investigating the role of IDH1R132H alone, there is a recent increase in research
efforts dedicated to identifying the role of other key genetic alterations that commonly
present alongside IDH1R132H in both low-grade gliomas and glioblastomas. Nuñez et al
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(2019) discovered that IDH1R132H promotes radioresistance in the context of ATRXLoss
and TP53 inactivation by suppressing gH2AX and 53BP1 recruitment to dsDNA breaks
as well as upregulating the expression of homologous recombination specific proteins
(ATM, RAD51, and BRCA1) for dsDNA break (DSB) repair.102 A follow up study
conducted by Kadiyala et al (2021) supported this conclusion by demonstrating that
combining

AGI-5198

(IDH1R132H

inhibitor)

with

ionizing

radiation

in

ATRXLoss/IDH1R132H glioma neurospheres reduced clonogenic survival and increased the
extracellular secretion of tumor damage associated molecular pattern molecules
(DAMPs) HMGB1, ATP, and calretinin.125 These results directly contradict previous
findings that IDH1R132H promotes patient survival by enhancing glioma dsDNA damage
caused by radiation therapy. Our results build upon the discoveries of Molenaar et al
(2015) by identifying an alternative mechanism for IDH1R132H inhibitor induced
radioresistance that incorporates the ATRX status of the cell. It will be interesting to
investigate the connections, if any, between IDH1R132H and subsequent 2-HG production
on RIPK1/RIPK3 mediated necroptosis. Taking into consideration the presence of ATRX
status of a patient’s tumor, we argue that combining IDH1R132H inhibitors with radiation
might serve beneficial for patients with oligodendrogliomas.
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Conclusion
In this study, we identified the potential for increased effectiveness of PRT vs.
XRT in overcoming the chemoradioresistant nature of GSCs in several human cell lines.
Using isogenic GSCs, we demonstrated that ATRXLoss promotes radiosensitivity
primarily via the RIPK1/RIPK3 mediated necroptosis cell death pathway. We also
provide evidence to support the conclusion that the role of IDH1R132H with regards to
radiosensitivity depends heavily on a GSC’s ATRX status. Specifically, IDH1R132H
promotes radiosensitivity and suppressed apoptotic/necrotic cell death in the context of
ATRXLoss; the exact opposite was found in GSCs containing IDH1R132H and ATRXWT.
Although our results suggest that PRT alone might be the best treatment option for
patients with astrocytomas, the combination of IDH1R132H inhibitors with PRT could
potentially serve as a highly effective novel treatment strategy to eliminate GSCs in
patients with oligodendrogliomas and overcome ATRXWT driven radioresistance.
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Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
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17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peerreviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes authorincorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
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appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the definitive final
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.

Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is defined by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
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Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
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RightsLink Printable License

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Dear Angel Garces
Thank you for contacting Promega Technical Services to request permission to use figures from
the RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay (JA1011) Technical Manual
(TM507) in your theses defense!
I consulted Promega’s legal team with respect to your request, who responded that, as long
as “© 2021 Promega Corporation. Reprinted with permission from Promega Corporation.” is
included in legends that contain Technical Manual figures, you may use these figures in
presentations or publications.
I would also encourage you to use the appropriate Promega trademarks for any Promega
products that you include in your presentation, figures, or publication. Those trademark
designations can be found at the end of any Promega Technical Manual, and you will find them
on pg. 25 of TM507.
Please contact me if I may be of further assistance.
Best Wishes,
Ryan
Ryan J. Olson
Technical Services Scientist
tel 608 277 4667
techserv@promega.com
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